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ABSTRACT
There is an ever-increasing awareness that the field of tissue engineering offers
many potential solutions to clinical problems. While advances along these lines have
been made, the design and implementation of an "off the shelf tissue is yet to be
realized.

Thus, the objectives of this work were largely aimed at the design and

fabrication of biocompatible, bioactive structures which could be integrated into existing
biomaterial products.
The electrostatic layer-by-layer (LbL) self-assembly technique was used to
incorporate biologically relevant molecules within controlled release systems, cell culture
platforms, and 3-D cellular capsules.

Two delivery systems were investigated to

determine the release of a model drug, dexamethasone (DEX). In the first system,
nanothin polyelectrolyte (PE) layers were applied to the micronized drug crystals as a
diffusion barrier. In the second system, DEX was physically entrapped within calcium
alginate microspheres which were further modified with PE layers. The fabrication of
cell culture platforms functionalized with nanothin layers of PEs, Ti()2 nanoparticles, and
the growth factor TGFPi was achieved through ultrasonic nebulization.

Finally,

individual cellular capsules were fabricated by elaborating the LbL process on
mesenchymal stem cell and human dermal fibroblast templates.
Materials characterization and cell culture testing were performed as preliminary
indicators of potential cytotoxicity. Release of the drug DEX was enhanced when

iii

iv
directly templated with polyelectrolyte

layers while DEX entrapment

within

polyelectrolyte-modified alginate microspheres reduced drug release by a factor of three.
An encouraging result of in vitro cell culture assessment was the distinct change in
fibrochondrocyte morphology when compared with positive and negative controls. An
ultrasonic nebulizer produced 14-layered cell culture substrates containing DEX, Ti02
nanoparticles, and the growth factor TGFpY In comparison with traditionally dipped
substrates, layer fabrication was expedited six-fold. Moreover, the positioning of TGFPi
within the layer architecture modulated cell behavior. For example, incorporation of the
growth factor as a terminal layer produced visible cellular extensions associated with
enhanced adhesion of human dermal fibroblasts (HDFs) to the substrates. The final
application of LbL was for production of nanothin cellular capsules. Layer fabrication
onto both HDFs and mouse mesenchymal stem cells (MSCs) was demonstrated with
acceptable cell tolerances although cell viability is likely affected by layer composition
and encapsulation time.
The major findings of this work not only demonstrated the feasibility of the
technologies, but also their ability to influence cellular behavior by exposure to specific
layer chemistries and architectures. The results are extremely promising for both further
fundamental research, as well as translation into products.

A major obstacle is

determining optimal parameters necessary to yield a given cell response. Moreover, cost
effectiveness must be addressed before clinical implementation of these systems is
realized. Undoubtedly, the work here provides an underpinning for the development of
additional capsules, microspheres, and substrates which could ultimately be integrated to
create novel, biocompatible, heterogeneous assemblies.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
As the life expectancy of an aging US population continues to increase, there is
great demand for therapies to heal fractures, replace joints and combat degenerative
diseases [1,2]. In particular, the complex architectural and functional characteristics of
orthopedic and dental tissues make attempts to repair, replace, and regenerate these
structures challenging. Impairments and disease states such as knee and hip fractures,
periodontal disease, and tooth decay require over 600,000 surgeries yearly to restore
functionality to the tissues of interest [3, 4]. Pure titanium and titanium alloys currently
represent the prime standard for dental and orthopedic implants. A tell tale sign of longterm implant success is early osseointegration, whereby newly formed bone or dentin is
directly apposed to the biomaterial surface, without the presence of a connective tissue
layer [5]. In general, healthy, youthful patients see positive outcome of their implant
surgeries, due to thier large bone density. However, older patients are more likely to
have low bone densities, and the outcome of their implant surgeries is often less than
desirable. Fibrous capsule formation and ultimately implant failure are noted in instances
where early osseointegration fails to occur. Thus, there is a need for expedited and
enhanced bone-tissue formation at the implant-tissue interface.

1

2
Numerous mechanisms have been proposed for enhancing bone apposition to
implant surfaces, to exert strict guidance over the cellular response.

The currently

applied theory is that implants of a higher surface roughness will provide a larger surface
area to which existing bone can attach. Roughened titanium surfaces have been achieved
through a number of methods, including plasma spraying, grit blasting, and acid etching.
Overwhelmingly, these methods have resulted in undesired side effects such as ionic
leaching into tissues, peri-implantitis, and surface embrittlement, despite their favorable
mechanical characteristics and ability to enhance the adhesion of bone [5]. Surface
modification of titanium surfaces with hydroxyapatite or other calcium phosphates can
generate the desired increase in surface area and roughness, with an additional benefit.
Hydroxyapatite and other bioactive ceramics can provide a biologically attractive layer
which recruits certain proteins and further enhances cell attachment.

Clinically, the

deposition of hydroxyapatite onto titanium surfaces has been achieved by a combination
of plasma spraying and grit blasting. The use of high heat and mechanical forces to
achieve the coating results in chemical and structural changes to the hydroxyapatite
crystal. Additionally, a major drawback of this technique is that it is unamenable to
coating implants with complex geometries [5]. The delaminating of the hydroxyapatite
coating from the titanium surface is yet another concern, as it can result in implant
failure.
Considering the limitations of current orthopedic therapies and treatments,
researchers have widely investigated alternative, more biomimetic approaches for
restoration and improvement of tissue function. Evolutions in biomaterials, as well as
advances in clinical medicine and basic science have made tissue engineering an intense
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area of focus. Numerous preliminary and longitudinal works have documented the
successes and practicality of engineered biomaterials, particularly those concerning
osseous and dental tissue replacement [4, 6-9]. Clear evidence indicates that tissueengineered products can drastically reduce the need for grafts, improve patient efficacy,
and likewise circumvent the associated complications such as repeated surgeries, and
immune rejection [10,11].
Despite significant advancement in the development of dental, orthopedic, and
reconstructive tissue-engineered products, there has yet to be one that is completely
biocompatible and long-lived. This state of affairs is due principally to limitations in our
understanding of cell differentiation, tissue formation, maturation, and remodeling. Thus,
the realization of widespread, clinically implemented tissue-engineered products hinges
on our obtaining a greater understanding of, and the ability to modulate cell-cell
interactions, cell-substrate relationships, as well as the subsequent effects on the
production of functional tissue. Each must be accounted for in the design of a tissueengineered product to ensure functionality over the long term.

1.1 The Cellular Niche
To successfully

engineer functional

neo-tissue, one must have a firm

understanding of the native cellular milieu. For example, the process of bone formation
is witnessed during embryonic development, human growth, and injury repair. Cell fate
processes, and ultimately tissue architecture are directly modulated through the
integration of biochemical and biomechanical signals present in the microenvironment,
namely extracellular matrix (ECM) ligands, and soluble factors. It is the interaction of
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these environmental cues with cell surface receptors that affect various signal
transduction pathways, regulate gene expression, and modify cellular behavior [12, 13].
Within physiologic connective tissues, cells secrete and maintain intimate contact
with the ECM, a highly organized, three-dimensional hydrated network of insoluble
proteins and polysaccharides [12, 14]. Proteins, such as collagen and elastin, are the
primary constituent of the ECM, supplying a structural framework for cells [14, 15].
There are of course, tissue specific variations in ECM content. Bone, for example, is
about 25% organic matrix, 5% water, and 70% hydroxyapatite (bone mineral). The
matrix of bone is approximately 90-94% collagen (I and V), before becoming
mineralized [15]. Other non-collagenous glycoproteins which impart specific functions
to bone and dentin are also found in the ECM, such as osteopontin, osteonectin, bone
sialoprotein, and their analogues [15].
In addition to providing mechanical integrity for tissue stabilization, the ECM
provides instructions for many other complex cellular behaviors through incorporation of
other biomolecules, to include polysaccharides classified as glycosaminoglycans (GAGs).
With the exception of hyaluronic acid, GAGs are covalently linked to a core protein,
forming a proteoglycan.

Proteoglycans are found both in the ECM and on the cell

surface. Notably, cell surface proteoglycans such as perlecan and biglycan modulate cell
adhesion, growth factor signaling, and ultimately tissue patterning [14, 16].
Among the many factors affecting the complex regulatory processes of cellular
growth, differentiation, and migration, cell adhesion to the ECM has been noted as one of
prime importance.

Cell adhesion is a prerequisite for cell viability, cell cycle

progression, and phenotypic expression. Abnormalities in the adhesive process often
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result in pathologies such as wound healing and blood clotting difficulties, as well as
malignant tumors and metastasis [17, 18]. In short, the lack of cell adhesion prevents
maintenance of optimal cell function.

In the context of tissue engineering and its

application of biomaterials, the ability to induce and control cellular adhesion and
associated responses directly affects the efficacy of the product.
It has been well documented that integrins, a class of membrane-bound linker
proteins, play a key role in anchoring cells to substrates [12, 14, 19]. The study of these
proteins has become a key area of focus in understanding cellular behavior, particularly
inflammatory and host responses in the context of biomaterials, implants, and tissue
engineered devices.

Integrins can interact with attachment factors found in serum,

adhesive ligands that have been engineered onto a surface, or ligands deposited by cells
[20].

1.2 Orthopedic and Dental Tissue Engineering
Contemporary tissue engineering strategies use a combination of cells,
biomaterials, and bioactive molecules to restore, modify, repair, or improve tissue
function [1, 10, 21, 22]. The synergistic relationship between the aforementioned
components is meant to recapitulate the cascade of events common to the natural tissue's
development so that cellular maturation is achieved, an extracellular matrix (ECM) is
produced, and tissue function is restored. Cellular conditioning is the fundamental aim of
a tissue-engineered system. This goal can be achieved by the use of a biomaterial scaffold
and differentiating factors alone, or in combination with one another to provide
mechanical stabilization, induce cellular signaling, achieve and maintain phenotypic
characteristics, and optimize tissue growth.
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1.2.1 Design Requirements
Numerous biomaterials, biomolecules, and cell sources have been characterized,
investigated, and identified as promising components of dental and orthopedic tissueengineered systems. Some widely used biomaterials include titania, calcium phosphate
and related ceramics. Examples of biomolecules shown to encourage bone formation
include members of the transforming growth factor (TGF) superfamily, glucocorticoids,
and components isolated from bone, such as dematerialized bone matrix. Overall, the
key to producing and organizing functional neo-tissue is the selection of an ideal
biomaterial that comprises osteoinductive, osteogenic, and osteoconductive factors.
1.2.1.1 Osteoinductive
component
One essential requirement for correction of bone tissue dysfunction is an
osteoinductive constituent [23]. Osteoinduction involves the de novo formation of bone in
response to biochemical signals. In this process, immature, undifferentiated cells are
recruited by chemotaxis, directed to proliferate, and eventually differentiate into boneproducing cells [24]. Soluble molecules such as bone morphogenetic proteins (BMPs)
have been examined for their role in bone induction, specifically the differentiation of
osteoprogenitor cells [11, 25-28]. Exposure to this class of proteins causes cells to
upregulate expression of the bone specific markers alkaline phosphatase and osteocalcin,
as well as produce mineralized structures. A recent study investigated the influence of
BMP2 on the osseointegration of roughened titanium screws into osteotomized rabbit

femurs. Over an 8-week period, greater bone ingrowth and implant calcification was
noted, when compared with non-BMP2 coated titanium implants.
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Other factors shown to direct cells of mesenchymal origin down an osteoblast
lineage include ascorbate, P-glycerol phosphate, Dexamethasone (DEX), and 1,25
dihydroxy, vitamin D3, and retinoic acid [11, 27,29, 30]. Of these factors, one favorable
approach is the use of DEX, a synthetic glucocorticoid.

As early as 1988, studies

involving glucocorticoids and mesenchymal cells were conducted when

Grigoriadias

reported the positive effects of glucocorticoids on expression of the bone phenotype [31].
Specifically, he found that DEX could cause the differentiation of fibroblast-like cells
into osteoblasts. The inclusion of DEX in or on an implant surface could prove very
useful in modulating the occurrence of peri-implantitis while also recruiting cells to the
implant area.
One concern with this and similar approaches is that the release of the drug or
biologically active molecule would need to be well-regulated. For instance, inclusion of
a bone-enhancing or anti-resorptive drug in an implant could lead to undesired overproduction of bone in the implant area [32]. There is evidence that in supraphysiologic
concentrations, growth factors can behave as pro-oncogenes, thus encouraging malignant
tumor formation, growth, and metastasis [23].
1.2.1.2 Osteogenic component
Osteogenic cell sourcing is a requisite player in both the immediate and long-term
feasibility of attempts to successfully engineer bone and dental tissues. A major obstacle
lies in our present inability to create a renewable source of cells for inclusion in tissueengineered products. Researchers have successfully isolated mature cells for use in auto, alio-, and xenotransplants. Harvesting cells directly from the patient eliminates immune
complications, however, autologous cells often have limited proliferative capacity, are
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difficult to sustain in culture and can result in significant site morbidity [33].
Alternatively, donor cells (either human or non-human) can be used. Indeed, there are
serious concerns with alio- and xenotransplantation, particularly the transmission of
viruses and infections [33]. Consequently, there has been a movement towards the use of
a cell source that can be readily grown, cultured extensively, and differentiated into
multiple cell types while producing little, if any immune response [1, 33, 34]
The use of stem cells in tissue engineering and other therapeutic strategies has
presented a solution to the problem of "regeneration competent" cells [33].

By

definition, stem cells are capable of self-renewal, and have the capacity to differentiate
into specific cell lineages [33, 35, 36]. Cell plasticity is a characteristic of natural
embryonic development whereby an initial cell mass undergoes several transitions to
ultimately produce tissues and organs. A great deal of debate surrounds the use of
embryonic stem cells, which are obtained from 3-5 day-old embryos. Although these
cells can be manipulated to give rise to nearly all cell types, ethical concerns about
obtaining cells from destroyed embryos have stunted their widespread use in therapeutics
[34]. Consequently, the use of stem cells from adult sources has become standard practice
in tissue engineering applications.
Adult mesenchymal stem cells (MSCs), typically derived from bone marrow,
have the capability to grow and renew over long periods of time [34, 35]. MSCs cannot
be isolated only from bone marrow or peripheral blood but also from a variety of other
sources like umbilical cord blood, adipose tissue and skeletal muscle [37]. While these
cells cannot differentiate into all cell types, a number of major cell types can be obtained.
These cells are said to be multipotent and can differentiate into a variety of mature cell
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types, including those that give rise to bone, cartilage, fat and muscle [35, 38-40]. The
lineage commitment is determined by the presence of suitable environmental cues. A
number of studies suggest that these cells elicit little, if any immune response, further
fueling their potential for use in therapeutics and clinical medicine [41-43]. Significant
effort has been devoted to investigating the competency of progenitor cell populations
derived from numerous sources including osseous tissues, dental pulp, and mesenchyme
[44-46]. In principle, MSCs and other progenitor cells can be incorporated into a tissue
engineered system and under appropriate stimuli—biological, chemical, and physical—
recruit local cells to needed sites, proliferate, and differentiate into the appropriate cell
type for functional tissue improvement.
Indeed, it is important to consider the morphological events concerned with the
production of the tissue of interest, for example, the evolution of stem cells to mature
osteoblasts or odontoblasts, and the environmental factors that facilitate these processes.
The precise mechanisms through which cells can differentiate, dedifferentiate and
transdifferentiate in response to environmental cues are largely unclear. Unveiling such
intricacies, however, will provide a clear foundation for the design of neo-tissues which
mimic native tissue.
1.2.1.3 Osteoinductive component
Osteoconductive materials support the migration, attachment, proliferation, and
differentiation of cells through microstructured components.

Many novel materials are

being developed to have osteoconductive features, and are typically similar in structure to
cancellous bone [47]. Calcium sulfates, calcium phosphates, and demineralized bone
matrix have been clinically implemented as osteoconductive biologies. Overwhelmingly,
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these materials are successful in filling segmental defects, but because they do not induce
bone healing, they have been recommended for use only as temporary void-fillers or
graft-expanders for orthopedic applications.

On the contrary, ceramics such as

hydroxyapatite which are chemically similar to bone mineral have seen a great deal of
success in supporting the attachment and ingrowth of dental tissue.

The release of

calcium phosphate into the local implant area increases the availability of biological
fluids and causes a layer of natural apatite to form on the surface. It is well documented
that this natural apatite serves as a supportive matrix for cellular attachment, and has lead
to increased clinical success when compared with similar uncoated dental implants [5].
Collagen can also be considered to have osteoconductive properties, as it has been known
to enhance the attachment and differentiation of osteoblast-like cells [23,48].
1.2.1.4 Other factors
Aside from the aforementioned design requirements,

additional parameters

should be considered in the design of an implant for bone or tooth repair, to maximize
patient compliance and implant success over a long period of time. Ideally, the scaffold
or implant should be fabricated so that it is able to withstand the mechanical loads that
are experienced in vivo. For example, a high elastic modulus may be desirable for a loadbearing implant while a high stress capability could be beneficial for a dental implant.
Still, more variations in the specific mechanical requirements would depend on the exact
shape and location of the defect. To date, the use of an antibacterial, biodegradable poly
(L-lactic acid) PLLA coating on titanium implants is being investigated, to reduce the
infection rates associated with traditional titanium implants and support implant longevity
[49]. Similarly, the ideal biological implant must be designed with a fine-tuned balance,
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such that other factors such thermal stability, nutrient and waste transport, and
vascularization are considered [2]. As has been shown here, biomaterials should be
engineered to harbor multiple properties to accelerate and optimize tissue formation
while also staving off infection and providing the desired mechanical stability. Certainly,
these promising approaches to tissue engineering will necessitate a great deal of
investigation and testing before they can be implemented clinically. Further experimental
strides in the areas of materials science, biology, chemistry and other areas will assist in
defining the particular clinical applications of newly developed products for tissue
engineering purposes.
1.2.2

Dental and Orthopedic
Biomaterials
An examination of the history of biomedical materials reveals that initial goals

were largely oriented toward implantation of inert materials. In the 1960s, polyethylene
and stainless steel were among the first implanted materials.

These first-generation

biomaterials were selected based on availability of common materials (wood, gold, etc.)
and many of the successes were accidental. Nonetheless, physicians desired to best
match the structural properties of the replaced tissue while exerting a minimal immune
response [50]. Among other implant materials used for orthopedic and dental tissue
stabilization, titanium provides the desirable characteristics of biocompatibility,
durability, and strength.

However, its implementation does not address the unique

problem of osseointegration. That is, complete and direct contact between bone and the
implant surface [3, 4, 51]. In many instances, the average lifetime of a bone fixation
implant is 10 to 15 years. Studies reveal that implant failure over time can be directly
attributed to inappropriate selection of the implant material [51]. This choice promotes
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the growth of both the desired bone tissue and unwanted soft, fibrous tissue. Fibrous
tissue growth inhibits osseointegration, and eventually leads to disunion of the implant
with surrounding tissue.
In the design of second-generation biomaterials, it was imperative to consider
bioinertness, along with a new parameter—bioactivity.

Bioactive components of an

implant were designed to "elicit a controlled action and reaction in the physiological
environment" and opened the door to development of bioactive glasses which reacts on
the surface to yield hydroxyapatite, a bone equivalent [50]. As mentioned earlier, porous
ceramics such as hydroxyapatite and calcium phosphates are being used to provide
osteoconductive support, thus facilitating the ingrowth of bone and associated
vascularized networks over time [50].
More recently, biostimulatory implantable devices are being tailored to bring
about directed cellular responses at the molecular level. The development of these thirdgeneration biomaterials has provided an excellent foundation for and has indeed
overlapped into the field of tissue engineering [50]. It is evident that ideally engineered
dental and osseous tissues must have the same complexity and properties as their native
counterparts at several length scales.
1.2.3

Influential Factors for CellSubstrate Interactions
The ability to influence cell-cell and cell-substrate interactions is key in the design

of tissue-engineered products [52]. It has become well accepted that cell-biomaterial
interactions are mediated by protein absorption on the material surface in the context of
topography, chemistry, and surface energy [23, 53, 54]. These parameters determine the
quality of cell adhesion, attachment, and morphology. Numerous experimental efforts
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have investigated cellular response to varied surface compositions and architectures;
however, there is a lack of consensus as to what surface features are superior to others for
enhancing cell growth and differentiation. It is clear that the degree to which certain
factors influence cellular response may be attributed to differences in cell type and
maturation state, fabrication methods, and culture conditions, among other parameters
[55].
1.2.3.1 Surface roughness
Surface roughness is an important mediator of cellular functions in the area of
biomaterials and tissue engineering, and can ultimately dictate the success or failure of an
implant [15, 56]. Several studies have shown that cells are preferential towards specific
topographies and roughness on both the nano- and micro-scales. For example, in a study
using osteoblast-like cells grown on poly(L-lactic acid) (PLLA) scaffolds, cellular
adhesion, uniformity, and growth were superior on island-patterned PLLA when
compared with a smooth fiat PLLA substrate [56]. Reportedly, osteoblast growth on
commercially pure titanium (cpTi) was enhanced on a rougher, machined surface while
periodontal ligament fibroblasts preferred smooth, electropolished cpTi [55].

Bone

marker expression, however, was highest on smooth polished Ti surfaces versus rough,
plasma-cleaned Ti [55].

In later work, osteoblasts cultured on Ti surfaces with a

roughness between 4 and 7 urn synthesized ECM, and subsequently produced
mineralized nodules [57]. A surface roughness of 1-2 urn is typical for oral implants,
having the ability to influence protein adhesion, cell attachment, and mechanical stability
[5]. Although cellular dimensions are on the order of microns, the portions of the cell
which interact with the extracellular environment are associated with the nano- atomic
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scales [15, 58]. Control of scaffold architectures and tissue implants in the nanoscale
range is being increasingly accepted as a key modulator of cellular function [52, 59]. For
example, in vivo, cells interact with nanoscale ECM topography[52, 60] Within the
corneal epithelial basement membrane, proteoglycan bridges are spaced in 60nm
increments [52]. To mimic the in vivo environment, efforts are being channeled towards
the production synthetic ECMs, such as Matrigel, which present natural nanoscale
topographies [52].

Moreover, a number of parameters to include peptide density,

substrate elastic modulus, and others have been implicated in affecting cell shape, gene
expression, and other cellular responses [61].
1.2.3.2 Surface chemistry and
surface energy
A well documented parameter known to critically influence interactions at the
implant-tissue interface is surface chemistry, or the presence of certain functional groups.
The ability to alter implant surface chemistry has clear implications for control over how
cells respond to certain functional groups; however, the exact signaling pathways
involved are largely unclear. One thing is sure: the way in which attachment factors and
proteins interact with different chemical surfaces has an effect on the subsequent cellular
attachment to a particular surface. For example, the incorporation of multiple calcium
phosphates onto a surface alters the attachment mechanisms for certain calcium-binding
proteins, and ultimately, the attachment of osteoblast cells [55]. The surface energy of a
biomaterial relates to the charge density and overall charge. There is support for the
hypothesis that cellular interactions are better on a hydrophilic, positively charged
surface, due to the chemical makeup of the cell membrane and its net negative charge
[62].

Based on this theory, cell adhesion is modulated by electrostatic interactions
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between the oppositely charged species (cell membrane and material surface), as well as
the covalent binding of proteins (attachment factors) to the substrate, which provide a
suitable environment for subsequent cell attachment. However, other factors aside from
surface hydrophobicity and charge must be considered to optimize cell adhesion [19].
Again, the much more complex processes, such as the manner in which proteins interact
with a surface dictates the cellular response. Thus, certain molecular conditions are
created with various surfaces to create a local surface tension and energy of adhesion
[57].
1.2.3.3 Surface stiffness
Cells have an inherent ability to probe their environment based on various
contractile mechanisms. Recent reports indicate that adherent cells show a behavior
known as mechanotaxis, or preferential migration toward stiff surfaces [63]. In response
to substrates with certain elastic moduli, cytoskeletonal reorganization in terms of myosin
and actin filaments occurs. Substrate stiffness determines integrin clustering and the
development of focal adhesions; thus cells are involved in a continual feedback process
of sensing and responding to their mechanical environment with contractile forces. It is a
well accepted fact that cell adhesion and spreading are increased with substrate stiffness,
and the role of stiffness is beginning to be investigated in tissue histogenesis, disease
states, and other phenomena [64, 65]. Myofibroblast differentiation has been shown to
depend on substrate elastic modulus, and other researchers are beginning to investigate
the elastic moduli of several other biomaterial surfaces for insight into how cellular
behavior and function are affected [63].
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As has been shown, numerous critical parameters for consideration must be
accounted for to create an optimal cellular milieu in terms of biochemical and mechanical
properties, towards to goal of properly repairing or producing functional neo-tissue [11,
21, 66]. These vastly different results concerning preferential cell substrates is proof that
certain cell types may be preconditioned for adherence to specific surface features, and
that material properties as well as fabrication techniques can profoundly affect cellular
response.

1.3 Specific Aims and Novel Aspects
The objective of this research was to address current limitations in orthopedic and
dental tissue implants, specifically generation and integration of properly organized neotissue at the implant interface. It is clear that organization at all levels—macro, micro,
nano, and atomic—has to be addressed if fully functional tissues are to be produced. In
particular, the cellular response to nanoscale multimolecular assemblies comprised of
soluble instructional factors and bioinert nanoparticles is investigated. It is expected that
the design of a cellular milieu which integrates the fundamentals of developmental
biology and nanotechnology will lead to increased understanding of how cells retrieve,
interpret, and respond to physicochemical information presented to them at the micron
and sub-micron levels.
The major challenge in terms of the current state of dental and orthopedic
implants is that commonly used materials have suitable mechanical properties, but lack
other, more advanced capabilities such as osteoconductivity [15]. Nanofabrication by
self-assembly provides the ability to engineer structures with defined mechanical,
biological, and chemical properties. Specifically, layer-by-layer (LbL) self- assembly is a
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promising mechanism which can be exploited for functionalization of cellular platforms,
scaffolds, and implant surfaces.

It is a facile method for creation of nanofilms up to

500nm thick, where the resultant monolayers can be comprised of a variety of ionic
substances including nanoparticles, enzymes, and proteins. Factors such as molecular
chemistry, component density, and the number of layers can be optimized to generate
specific film properties and encapsulate biomolecules for controlled release and targeted
delivery [67-70]
It was hypothesized that through the use of LbL assembly, cell scaffolds could be
functionalized with instructional molecules in an appropriate biocompatible carrier to
modulate

cellular

microenvironment

differentiation
for

improved

and ultimately
or

enhanced

recreate

a

suitable

cellular

function.

in vivo
Successful

implementation of such a system will lead to tailored therapeutic products, which have
the ability to produce properly organized orthopedic and dental tissues. The development
of an "off the shelf tissue-engineered product is promising, and in the near future, such
products will reduce hospitalization and health care costs associated with surgeries and
drug therapy while increasing patient quality of life.
To improve upon the current limitations of orthopedic tissue engineering systems,
specifically elucidating certain factors which play a role in crafting the cellular
microenvironment, three experimental approaches were investigated. The global project
objective and hypothesis were addressed by the following specific aims:
Aim#l:

Cells respond to biomolecules during development, growth, and repair.
The construction controlled release systems containing a model drug,
Dexamethasone (DEX) is described. Two schemes are evaluated, direct
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surface modification of the drug with nanothin polyelectrolyte layers, and
creation of DEX-loaded calcium alginate microspheres, further modified
by deposition of polyelectrolyte layers.
Aim #2:

Nanomaterial surfaces can be used as drug and biomolecule carriers. The
development of biocompatible cellular scaffolds with varying surface
chemistries and embedded chemical signals is presented. Using selected
biocompatible polyelectrolytes and nanoparticles, the traditional LbL
technique is modified using nebulization as a means of layer deposition.

Aim #3:

Encapsulation of cells within protective matrices can be exploited for
grafting and transplantation. The results of individual fibroblast and
mesenchymal stem cells encapsulation within biocompatible thin-film
shells, along with the embedding of signaling molecules within the cell
coatings are discussed.

The global challenge at the forefront of tissue engineering is to design a system
which combines cells, diffusible signals and supportive architectures such that defective
tissue is produced by inducing histogenesis in a specified location. Collectively, these
analyses provide a means through which electrostatic LbL assembly fundamentals can
tailor substrates in a biologically relevant fashion, assess in vitro cellular behaviors, and
examine their potential use for in vivo studies for dental and orthopedic tissue
engineering applications. Specifically, the implications of this work are far-reaching,
such as the ability to expeditiously coat implant surfaces with composite materials for
enhanced functionality and the promise of improving viability and functionality of
transplanted cells by priming in a 3-D environment.
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It is hoped that the integration of this work with fundamental research
concerning cell sourcing, scaffold characterization, tissue grafting, identification of
molecules that control the cell environment, and developmental biologic processes will
impact the development and clinical implementation of tissue-engineered technologies.

1.4 Dissertation Overview
This introductory chapter is followed by a literature review, encompassing a
discussion of the fundamentals of LbL assembly and its use in surface modification for
biological applications. In Chapter 3, the basic working principles for materials and
cellular characterization are presented. Chapter 4 addresses the details of the first aim,
specifically the preparation and characterization of calcium alginate microspheres and
directly modified Dexamethasone aggregate systems for controlled release applications.
Chapter 5 discusses cellular response to growth on multilayered platforms fabricated by
nebulized LbL. The evaluation of LbL for creation of biocompatible cellular capsules is
addressed in Chapter 6. Last, Chapter 7 provides a summary of the work, conclusions,
and future directions.

CHAPTER 2
SELF-ASSEMBLY IN TISSUE ENGINEERING
This chapter details recent research efforts aligned with the major topics of the
current work. The fundamentals of LbL assembly, as well as existing applications to cell
culture and controlled release applications are addressed.

2.1 Self-Assemblv of Thin Films
Fabrication of thin films via self-assembly of molecules is a powerful technique
with gaining popularity in biomaterials applications. The ability to manipulate molecules
on the nano- and atomic levels provides interesting possibilities for generation of novel
materials, which may impart certain cell-friendly properties that encourage superior cell
adhesion, modulate cellular differentiation, or promote cell motility.

The basis of

multilayered thin-film self-assembly is spontaneous interactions of molecules, in the form
of ionic, covalent, van der Waals, or hydrogen bonds, which mimics the bottom-up selfassembly processes found in nature [71].

Advantages of self-assembly techniques

include resistance to impurities, and limited architectural defects.

Such is the case

because of the thermodynamics and kinetics of film assembly [71]. Individual molecular
chemistry and properties determine bulk film properties and functions.

Thus, in the

context of tissue-engineered products, film architectures can be tailored to generate novel
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structures which may enhance implant coatings, improve wound dressings, or support the
timed release of drug molecules.
Construction of thin-films fabricated using the Langmuir-Blodgett (L-B)
technique and self-assembled monolayers (SAMs) has been thoroughly investigated in
the past. However, pioneering work by Decher et al. using the layer-by-layer (LbL) selfassembly method has shown promise for generation of highly organized multilayer thin
films based on alternate adsorption of molecules in oppositely charged aqueous solutions
[72]. Over the years, this technology has been adapted to incorporated nanoparticbs,
enzymes, DNA, cells, and biological molecules, among other charged moieties [73, 74],
Moreover, it is superior to the other methods of thin film assembly because of its mild
assembly conditions, facile principle of operation, and ability to generate precisely
organized multilayers with advanced functionality.
To give some perspective on the uniqueness of the LbL technique, L-B films and
SAMs are briefly discussed.

The Langmuir-Blodgett technique involves transfer of

molecules from a water surface to solid substrate. L-B films have a high degree of
molecular order, a desirable characteristic of thin films [75]. Despite the fact that film
thickness of 5 to 500 nm can be produced, L-B films have several limitations. These
films are restricted to amphiphilic molecules, can be deposited only on planar substrates
of a few square centimeters, and are easily disrupted by thermal or chemical
environmental changes [71]. The fabrication of SAMs is based on the interaction of thiol
or silane functionalized compounds with a surface. With this technique, films of 2-5 nm
can be generated by immersion of a gold or silicon substrate in a solution containing
appropriate functional groups. Film buildup can take anywhere from several seconds to
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several hours, based on the molecules and solvent properties.

The requirement of

specific substrate chemistries and functional group modification of layer constituents,
coupled with the inability to create films thicker than 2-5 nm, limits the use of SAMs to
few industrial applications.

2.2 Nanofabrication by LbL Assembly
The LbL technique produces nanofilms up to 500 nm thick by capitalizing upon
electrostatic and covalent interactions between a substrate and subsequent molecular
monolayers.

These monolayers may be comprised of a variety of ionic substances to

include nanoparticles, enzymes, and proteins. Factors such as the type of substance used
to form layers, the component density, and the number of layers can be optimized to
generate specific film properties. Because LbL is simple, economical, and versatile, it is
being used more and more in the assembly of many types of thin films [67].
2-2.1 Fabrication of LbL Films by
Substrate Dipping
Substrate dipping, the traditional method of LbL assembly onto planar surfaces is
straightforward. Beginning with a charged solid template, the surface is immersed in a
polyelectrolyte (PE) solution of opposite charge. The layer adsorbed carries the charge of
the solution, due to overcompensation of the surface charge.

A critical parameter

involved in LbL film assembly is solution concentration; a minimum concentration is
required so that numerous ionic groups remain exposed at the surface to reverse the
previous charge. An intermediate washing step in ultrapure water is required for removal
of weakly adsorbed species [76]. Subsequent layer deposition then occurs in a similar
manner, again immersing the newly charged substrate in a solution of opposite charge
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followed by an intermediate rinse. Multiple architecture films containing PEs, proteins,
DNA, inorganic particles, and virtually any other charged species can be engineered with
LbL technology.
Later work in the field has adapted the LbL technique to non-planar substrates,
such as colloidal particles, enzymes, dyes, drugs and cells [69, 74, 77, 78]. In a similar
manner as with planar LbL assembly, the charged template is immersed in an oppositely
charged solution. The only difference is that for non-planar substrates, intermediate
washings are carried out via centrifugation, where the centrifugation time and speed are
dependent on the size and fragility of the template structure.
One very practical outcome of LbL technology is the ability to tune individual
layer thicknesses. Highly standardized layer thicknesses of one to several nanometers
can be generated based on the film's chemical composition and assembly pH. These
thicknesses can be further modulated by varying the ionic composition of the species
solution, where low ionic concentrations solutions tend to result in the thickest films [79].
Reportedly, incorporation of low salt concentrations between 0.1 and 1 M slightly
neutralizes the PE chains, causing formation of large loops [80]. The requisite time
required to achieve PE layer deposition at a thermodynamic minimum is typically 10 to
15 minutes. After the saturation time, any additional deposition will not lead to increased
layer buildup. This phenomenon is what makes the LbL technique extremely accurate.
In aqueous solution, LbL films have been shown to double in thickness; in the dried state,
approximately 5-10% of water remains within the film architecture [81]. Nonlinear film
growth is typical with the first few PE layers, because of uneven charge densities. In this
segment of film buildup, thin and unevenly distributed layers are typical until sufficient
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charge covers the entire substrate area. Therefore, precursory layers are typically used for
accurate characterization of film kinetics [82].
2-2.2

Fabrication of LbL Films by
Spraying
The steady-state adsorption of PEs onto a charged substrate is the rate-limiting

step for the LbL technique. Traditionally, it is necessary to allow a deposition time of up
to 20 minutes for each PE layer, followed by several rinses in pure water at 5-10 minutes
each [83]. In recent years, researchers have found that aerosol spraying of PEs onto
substrates significantly reduces the LbL deposition time while maintaining similar layer
characteristics as conventional substrate dipping [83]. In this manner, the spray axis and
substrate are oriented perpendicularly to one another. Due to drainage of excess material,
the rinsing step can be omitted while retaining film quality and integrity. Others have
extended the spray technology beyond traditional PEs to include colloidal nanoparticles
and dendritic compounds [84]. More recently, spraying by ultrasonic nebulization has
been explored as a tool for expedited LbL assembly [85].

Details regarding the

mechanistic differences between spraying and conventional dipping of electrostatically
assembled films are still poorly understood. Yet, the advantages and further possibilities
of sprayed multilayers are sure to be continually probed for industrial and biological
applications.

2.3 Multilayered LbL Films for Biological Applications
Conventionally, LbL was used for production of systems with novel optoelectronic characteristics [86]. However, as early as 2000, the promise of LbL technology
for biological systems was realized.

Serizawa et al. were among the first to study
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coagulation properties of whole human blood on PE films comprised of chitosan and
dextran sulfate [87]. Since then, many others have studied a variety of biological systems
at the interface of well-organized LbL-assembled platforms.
The use of multilayered LbL assembled films offers numerous advantages over
other self-assembly methods, particularly the ability to modify surfaces independent of
their geometry, thus opening the door to production of surfaces with enhanced
biocompatible functionality. Today, the versatility of LbL technology in the context of
designing unique tissue-engineered products is evidenced by the immense variety of
materials incorporated into films, including nanoparticles, protein-growth factors, and
other biomolecules to achieve a desired biological effect [67, 68, 88-93].
2.3.1

Cell Culture on
Polyelectrolvte LbL Films
Uniquely coated biomaterial surfaces are of increasing interest for the engineering

of biomedical systems, especially dental, orthopedic, and wound-healing applications.
The use of LbL films as coatings in biological applications offers the ability to tune
surface chemistry, topography, and other physicochemical parameters in a desirable
manner. Assessment of protein-biomaterial surface interactions is an important first step
in controlling immune responses, cell adhesion and other, more advanced cellular
functions [94]. Therefore, protein adsorption onto LbL films consisting of various PEs is
an intense area of research because of the promising implications for biomaterials.
The design of protein- and cell-selective coatings has been realized by many
researchers. Reportedly, serum protein adsorption was detectable on PLL-terminated
films but not on PGA-terminated films [95]. This study further found that the adhesion
force of chondrosarcoma cells to PLL- and PGA-terminated films followed suit. That is,
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cells cultured on PLL-terminated films in the presence of serum showed noticeable
adhesion forces, with the highest forces on films of the architecture (PLL/PGAVPLL
while, cells cultured on PGA-terminated films demonstrated little to no substrate
adhesion. Tryoen-Toth and colleagues investigated the growth of osteoblast-like and
periodontal cells on LbL films comprised of several PEs, including PLL and PGA [96].
Based on morphological observations, expression of phenotypic markers, and cell
adhesion assays, their findings indicated that both PEs were suitable film endings, and
could be used as coatings for implantable medical devices. PE films with non-specific
protein resistant properties have been fabricated by employing a terminal layer of PLL-gPEG.

However, in this same study, biotinylation of the PLL-g-PEG layer allowed

specific binding to the protein streptavadin [97]. A multilayered film consisting of the
natural PEs, PLL and HA was produced on chitosan-coated glass towards the goal of
fabricating a completely biocompatible thin-film [98].

In this instance, blood

mononucleolar cell adhesion was decreased on PLL/HA films when compared with
adhesion on standard tissue culture plates, likely because of the large volume of HA
incorporated within the film assembly.

Cai and colleagues demonstrated that the

biocompatibility of PDLLA surfaces could be enhanced by the electrostatic deposition of
chitosan-containing films [99]. Overall, the protein interaction and apparent cellular
tolerances for various PE surfaces could be due to a number of underlying factors,
including surface chemistry, roughness, and inherent cellular makeup, however, many of
the details regarding these influences are currently unknown.
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2.3.2

Cell Culture on Nanophase
LbL Films
Although traditional multilayered PE films have been shown to impart some

degree of preferential cell adhesion at their surface, these films lack an important
parameter which has been shown to affect cellular

function—nanotopography.

Incorporation of colloids and nanoparticles within the LbL film allow for the presence of
this critical component by directly influencing surface roughness. Moreover, a high
degree of structural control can be attained through incorporation of nanoparticles within
the film [67]. It was demonstrated that by coating CdTe nanoparticle/polycation films
with layers of collagen/poly(acrylic acid), cell viability was achieved on otherwise
cytotoxic nanoparticle films [100]. In another example, human dermal fibroblast and
mesenchymal stem cell adhesion was notably largest on LbL films embedded with TiC»2
nanoparticles when compared with controls. Moreover, incorporation of an increasing
number of Ti02 nanoparticle layers resulted in even greater cellular adhesion, largely due
to the increased surface area available for cell attachment generated by successive
nanoparticle layers [68, 101].

Most recently, mouse neural stem cell growth and

differentiation has been achieved on carbon nanotube/PE multilayer films.

Cellular

function on these films was similar to that on the traditionally used poly(L-orthine)
substrate for neural cell growth. From the results of their work, it is anticipated that the
signal transduction capabilities of carbon nanotubes will assist in the generation of unique
neuroprosthetics [102]. Unfortunately, only a limited number of reports which aimed to
incorporate inorganic nanomaterials within LbL films for biological applications.
However, the efforts highlighted here have clearly established the potential for creation
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of novel, hybrid nanobiomaterials. They offer the possibility to preserve the nanoparticle
material properties while also imparting biocompatibility.
2.3.3

Incorporation of Bioactive
Species in LbL Films
Investigations into LbL films functionalized with peptides, proteins, growth

factors and other biologically relevant molecules have presented promising opportunities
to overcome challenges and obstacles associated with tissue-engineered products, such as
peri-implantitis, seamless integration of neo-tissue into existing tissue, uncontrolled
tissue growth, and short half lives regarding biomolecule delivery [90, 103].
Interestingly, anti-inflammatory agents such as a-MSH and priroxicam have been
incorporated into PE films [89]. The authors showed a dose-dependent response to these
agents, whereby human monocyte response was controlled by the position of the
molecule within the film. Alternation of the antimicrobial peptide HEWL with PLGA in
the form of an electrostatically assembled film was shown to decrease the colonization of
the bacterium M. luteus, with increasing affectivity noted for films with larger HEWL
content [91].

The facile embedding of ECM proteins in multilayer films has been

acknowledged. Fibronectin-terminated LbL films of varying compositions were shown to
affect the morphology of human umbilical endothelial cells [93]. Similarly, collagen-I
LbL films supported the growth of C2C12 and PC 12 cells [104]. Films containing other
proteins including a-lactalbumin, human serum albumin, myoglobin, ribonuclease A, and
lysozyme have also been assembled using the LbL technique [105]. The growth factors
BMP2 and TGFPi were successfully incorporated into multilayered films, having the
ability to differentiate embryoid bodies into cartilage and bone when the two proteins
were combined within the same film [88]. Acidic FGF/heparin multilayer films were
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shown to enhance collagen I production in fibroblasts, specifically when cultured on five
bilayered substrates [90]. Furthermore, the films retained their functionality after being
stored for three months at -20 C. In another study, BMP2 release from PAH/DNA and
PDL/DNA multilayer films was shown to be greatest when incorporated after each
bilayer. Rat bone marrow cells were differentiated into osteoblasts on these films, where
calcium deposition was controlled by the specific BMP2 loading modality [92].
Still in their infancy, these efforts are limited to acute analyses of cellular
response on protein-embedded LbL films. It is proposed that numerous factors affect
protein release from the film architectures, including diffusion, film degradation, and
desorption [89,106]. The signaling pathways through which cells function in response to
these films have yet to be folly elucidated, and are critical for prediction of in vivo
performance and clinical implementation.

These exemplary studies, however,

demonstrate the promise of LbL-assembled coatings for the control of cellular
interactions with biomaterials.

CHAPTER 3
METHODS AND INSTURMENTATION USED
FOR EXPERIMENTAL QUANTITATION
AND ANALYSIS
This chapter briefly describes the principle of operation for the methods and
instrumentation used in quantitation and analysis of experiments conducted in this
project.

3.1 Materials Characterization Methods
A number of techniques that provide information about LbL film characteristics
during and after film assembly. The specific techniques selected are dependent upon the
types of data desired. Adsorption kinetics for thin film assembly can be easily monitored
by the quartz crystal microbalance (QCM) method, which detects changes in mass on the
order of nanograms,

^-potential measurements are taken at each deposition step to

provide information about colloidal surface charge properties. Another method, UVvisible spectroscopy generates a linear increase in absorbance with respect to analyte
concentration and is helpful in quantifying release characteristics. Various microscopic
techniques to include confocal microscopy and atomic force microscopy (AFM) are
helpful in visualizing nanofilms properties and surface characteristics for assessment of
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film morphology and quality. Ultrasonic nebulization, one of the novel methods used in
this work to expedite LbL film fabrication is discussed in principle.
3.1.1 Quartz Crystal Mtcrobalance
Technique
The Quartz Crystal Microbalance (QCM) technique has been widely used for
real-time characterization of LbL films comprised of PEs, proteins, and other
macromolecules. A QCM is a quartz crystal covered with metal electrodes. When an
alternating electric current is applied across the electrodes, the crystal oscillates at its
fundamental frequency. Upon deposition of mass onto the QCM surface, the oscillation
frequency is dampened. This decrease in frequency can quantify the amount of mass and
thickness deposited, based on empirical relationships derived from the well-known
Sauerbrey equation [107,108]:
Ant (ng) - -0.87 % Lf (Hz) and At (nm) = -0.017 x Af (Hz).
Therefore, a 1 Hz decrease in oscillation frequency corresponds to deposition of 0.87 ng
in mass or 0.017 nm in thickness. The deposition of proteins, PEs and nanoparticles was
monitored through QCM analysis for this work.
3.1.2 Zeta-Potential Analysis
The surface charge of colloidal suspensions is important for monitoring LbL
assembly, and is accomplished through zeta- (Q potential measurements. Simply put, £potential is the measure of the electrostatic interactions within a colloidal system. Under
an electric field, particles move through solution to an electrode of opposite charge, and
^-potential measures the potential difference between the particle and the dispersion
medium.

Thus, ^-potential is directly influenced by pH, ionic strength, and other

environmental conditions. It is commonly accepted that particulate dispersions with C,-
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potential values with absolute values of 30 mV or more are stable due to the large degree
of electrostatic repulsion [109]. In this work, ^-potential measurements were used to
monitor film interactions with colloids and cells.
3-1.3 Ultraviolet-Visible
Spectroscopy
Ultraviolet-visible (UV-vis) spectroscopy is used to quantify the amount of an
analyte within a sample, and was used in this work specifically for quantitation of DEX
release. When light at a specified wavelength (UV, 200-400 nm or visible, 400-800 nm)
is passed through a sample, a characteristic optical behavior is observed. The light
intensity is altered based on the amount photons that are transmitted through or absorbed
by the sample. The Beer-Lambert law describes the relationship between the intensity of
light passing through a sample and its concentration:
A = s • c * I = log (-J-)

Thus, the absorbance (A) of a sample is directly proportional to the absorption coefficient
(e), concentration (c), and the path length (1), at a specified wavelength. In a typical
acquisition setup, 8 and I are constant, so that the concentration directly influences
absorbance [110].
3.1.4 Laser Scanning Confocal
Microscopy
Laser Scanning Confocal Microscopy (LSCM) provides the ability to view thin
optical sections, an unavailable characteristic in conventional fluorescence microscopy.
This optical slicing is accomplished in two ways: single-point illumination of the sample
and elimination of out-of-focus light at that point. Laser light passes through the
microscope objective, exciting the fluorescent sample; the emitted light passes back
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through the objective and a pinhole aperture, thus accepting only the in-focus light at that
sample point. The sample is scanned in this way at various points in the x- and ydirections, to reconstruct the image. Furthermore, a 3-D image can be produced by
combining 2-D images at various depths [111]. In this study, LSCM was used to image
DEX aggregate geometry.
3.1.5 Atomic Force Microscopy
The Atomic Force Microscope (AFM) uses a small probe placed close to a sample
surface for acquisition of topographic information at high resolution. The AFM operates
by measuring changes in repulsive or attractive intermolecular forces between the probe
and the sample surface. In the repulsive "contact" mode, the probe touches the sample,
and deflections in height are recorded as scanning occurs. In "non-contact mode", which
was used for this work, the probe vibrates at a fundamental frequency. Changes in the
frequency as the probe approaches a sample surface are correlated to changes in the
attractive forces, ultimately gleaning information about topography. The characterization
of sample surfaces in this way is non-destructive, yet highly resolved [112].
3.1.6 Ultrasonic Nebulization
An ultrasonic nebulizer (UN) uses high-frequency ultrasonic waves to convert
liquids into aerosol, with typical output volumes of 1-6 mL/min and particle sizes of 1-6
um. The power setting determines the output while the frequency at which the UN
operates determines the particle size. The UN used in this particular study requires that
the solution be placed within a nebulizing chamber. A fan then evacuates the aerosol
from the chamber and through plastic tubing [113]. An UN was explored as a means of
expediting layer deposition in the LbL process.
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3.2 Cellular Characterization Methods
Techniques used to determine cellular response are numerous. For example, the
Live/Dead Assay is used as a measure of cell viability and can provide critical
information pertaining to cytotoxicity. Assays such as WTS-1 and MTT can give an
indication of changes in cellular metabolic activity after a given treatment. Pico-Green
can quantify cellular double-stranded DNA content and immunocytochemistry can be
employed to confirm the presence of extracellular matrix proteins or other markers
indicative of changes in cellular function. In this study, these methods were used to
analyze changes in cellular response in a comprehensive manner.
3.2.1 Live/Dead Assay
The Live/Dead Assay provides a simple method for distinguishing between live
and dead cells, through the use of a two-color fluorescence based technique. Live cells
convert the non-fluorescent calcein acetoxymethyl (Calcein-AM), into the molecule
Calcein, which emits a green fluorescence. Dead cells, having damaged membranes,
fluoresce red when their nucleic acids bind to ethidium homodimer-1 (EthD-1) or
propidium iodide (PI) [114]. This technique is desirable because of low background
fluorescence, and its ability to be used for extremely high throughput quantitative
analysis such as flow Cytometric.
3-2.2 Cellular Metabolic Activity
Assays
Two colorimetric assays for the measure of cellular viability were used in this
work, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-l ,3-benzene disulfonate
(WST-1) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
[115]. These assays are based on the cellular conversion of the tetrazolium salts into
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colored formazan products.

WST-1 forms a yellow-orange product with a peak

absorption between 440-460 nm while the MTT precipitate is blue-purple, having a peak
absorption around 570 nm. The product of WST-1 is water soluble, unlike that of MTT.
The fact that a solubilization step is not required for the WST-1 Assay can be beneficial;
however, not all cell types can process the molecule owing to the wide-use of MTT as a
standard measure of cell metabolic activity [115].
3.2.3 PicoGreen Assay
PicoGreen is a fluorescent nucleic acid stain used to quantify double-stranded (ds)
DNA within a sample [116]. This assay is highly sensitive, able to detect as little as 250
pg/mL dsDNA within a 200 uL sample.

A linear relationship between dsDNA

concentration and fluorescence emission at -520 nm provides quantitative information.
The contribution of RNA, salts, proteins, and other molecules to the fluorescence signal
is minimal with this technique, when compared with traditional Hoechst- or UV
absorbance-based dsDNA quantification methods.

Thus it is a viable method for

quantitation of DNA under various environmental conditions.
3.3.4 Immunocytochemistry
Immunocytochemistry (ICC) is a molecular biology technique that detects
specific cellular antigens through the use of antibodies. With ICC, the precise location of
the target antigen within a cell can be determined and visualized. To execute ICC, cells
must first be fixed, to retain the natural positioning of the antigen. Subsequently, a
primary antibody is applied. The primary antibody can be tagged with a secondary
antibody which is further coupled with a chromagen, fluorescent marker, or enzyme,
depending on the intended application.

The ICC technique can be adapted to the
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simultaneous detection of several antigens through the application of distinctly different
antibodies and markers [117].

CHAPTER 4
CONTROLLED RELEASE OF DEXAMETHASONE
USING ELECTROSTATIC LAYER-BY-LAYER
ASSEMBLY
4.1 Introduction
Tissue-engineered

constructs for

improvement

of function

in dental,

maxillofacial, and orthopedic pathologies have received much attention in recent years.
Although researchers have improved the design of biocompatible, mechanically apt
materials, implant failures still occur, largely from inflammation as a result of wear at the
surface, loosening, or microbial contamination over the long-term [118, 119]. Control
over the implant-host response is critical in extending the longevity of the implant, and
improving patient quality of life. The delivery of glucocorticoids by injection is a
clinically effective treatment for control of inflammation; however, the duration and
potency needed to achieve a certain level of relief is still uncertain [120]. Dexamethasone
(DEX), for example, has potent anti-inflammatory abilities but it causes serious systemic
side-effects such as increased risk of infection when dosages are not well-regulated [121,
122]

Recent studies have attempted to achieve targeted and timed release of drugs,

proteins, and other therapeutics in the context of tissue engineering. Many advanced
drug-delivery

systems

operate

on

this
37

principle

of

controlled-

release.
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Controlled-release technology is advantageous over the traditional drug
formulations because a certain amount of the biomolecule is delivered over a specified
time in a predictable manner. Such systems can augment bioavailability and specificity
while maintaining a specified therapeutic range [123, 124]. Numerous controlled-release
systems for inclusion tissue-engineered constructs have been investigated over the past
several years [124-128]. It has been well established that delivery systems using
biodegradable polymers offer great promise for use in biomaterial applications.

In

comparison with polymers such as poly(lactide-co-glycolide) (PLG) that are hydrophobic
and processed under harsh conditions, hydrated polymers known as hydrogels are
hydrophilic, can be easily fabricated, and have protein and polysaccharide constituents
comparable to those of natural ECMs [129,130].
Hydrogels are a class of polymers that swell when they come in contact with
water. Parameters such as the structure, chemical composition, and the method and
degree of crosslinking, can affect biocompatibility, material properties and performance.
In addition, the interface between the biomaterial and surrounding tissue is thought to be
improved with hydrogel use, as the crosslinking provides increased mechanical stability
at implant site [129, 131]. A great deal of focus has been on the development of
degradable hydrogels for drug delivery and tissue engineering applications, mainly as this
type of system would not necessitate the removal of an implant. Synthetic hydrogels
including poly(lactic acid) (PLA), poly(ethylene glycol) (PEG), and poly(vinyl alcohol)
(PVA) offer extreme control of mechanical properties and have been investigated for
entrapment of growth factors and cells [131,132]. Natural hydrogels such as hyaluronic
acid (HA), alginate, and collagen are particularly attractive for use as delivery vehicles in
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a tissue-engineered system because they are components of, or are molecularly analogous
to portions of the natural ECM [129]. Moreover, these molecules are capable of directing
cellular behavior, and can be naturally degraded by proteases such as collageriase and
hyaluronidase, allowing the process to be facilitated by cells in the engineered tissue
[129,130].
Alginate hydrogels have been widely explored as vehicles for the delivery of
drugs, enzymes and cells because of the mild gelling conditions and low toxicity [129].
Alginate, derived from seaweed, is a linear polysaccharide composed of (1-4) linked P~Dmannuronic acid (M) and a-L-glucuronic acid (G). Crosslinking occurs when divalent
cations such as calcium, barium, or strontium, interact with the G monomers [129, 130].
Entrapment of glucose oxidase within calcium alginate microspheres has resulted in
successful retention of the enzyme's bioactivity [133].
Recently, researchers have described methods by which DEX could be
encapsulated using LbL assembly [69, 70]. Surface modification using this technique
provides a diffusion barrier to retard the release of the molecule from both aggregate
systems and alginate hydrogels [69, 77, 133, 134]. LbL exerts precise control over
controlled-release systems since each adsorbed layer is a few nanometers in thickness.
Moreover, the resulting thin films can be tailored to destabilize under specific conditions
such as pH, based on the isoelectric points of the layer constituents [77].
Thus, the goal of this work was to construct a controlled-release system
containing DEX and evaluate the potential for its use in a tissue-engineered construct.
The application of LbL for surface modification of micronized DEX aggregates and
dexamethasone-loaded calcium alginate microspheres (DLCAMs) was investigated.
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Incorporation of nano-thin layers onto DEX aggregates provides enhanced drug release
while layer deposition onto DLCAMs retards drug release, each of which could be
valuable for a specified therapeutic application. Acute in vitro assessment of the DEX
aggregate system is also, included as a means of establishing initial biocompatibility and
cytotoxicity results.

4.2 Materials and Methods
We selected two schemes for delivery, (i) physical immobilization of DEX within
calcium alginate microspheres, which were further modified with nanothin films using
LbL, and (ii) direct adsorption of nanothin films onto DEX aggregate cores. Through use
of the LbL process, electrostatic interactions cause the template surface to carry the
overall charge of the solution in which it is immersed. The newly charged template can
again be immersed in an oppositely charged solution, and the process can be repeated
until a desired thickness or layering architecture is achieved. The ability to apply this to
any charged surface makes it attractive for drug delivery applications.
4,2.1

Preparation of Potyelectrolyte
and Drug Solutions
The polyelectrolyes poly(dimeththyldially ammonium chloride), 20% (PDDA,

MW 400,000), polystyrene sulfonate) sodium salt, 30% (PSS, MW 70,000), chondroitin6 sulfate (CS, MW 60,000), protamine sulfate from salmon salt (PS, MW 5,000-10,000),
gelatin type-A (GelA, MW 50,000-100,000) and gelatin type-B (GelB, MW 50,000100,000) were purchased from Sigma Aldrich and prepared at a concentration of 1-5
mg/mL in either deionized water for ^-potential characterization (DI H2O) or 10 mM
phosphate buffered saline (PBS) for other experimental efforts.

DEX (MW 392.46,

41
Sigma) was prepared in DIH2O and diluted in culture media or DI H2O to give a desired
final concentration. Thefluorescentmarkerfluorescein-5-isothiocyanate(FITC, Sigma)
was used to label polyelectrolytes for ease of visualization in fluorescence microscopy.
4.2.2 Fabrication of Calcium
Alginate Microspheres
Calcium alginate microspheres were fabricated in a manner similar to that used by
Brown et al. for entrapment of glucose oxidase (see Appendix A for detailed information)
[133]. DEX was incorporated within sodium alginate matrices while stirring with a
propeller style mixer (Figure 4.1). A water-in-oil emulsion was formed with the use of
isooctane, and ultrasonication was used to reduce microsphere size. Calcium chloride
was added as a final cross-linking agent and the microspheres were washed in deionized
water before experimentation.

Figure 4.1. Schematic of dexamethasone-loaded calcium alginate microspheres, adapted with permission
from Brown et al [133].
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4.2.3 Surface Modification of Release
Systems Using LbL Assembly
Deposition of polyelectrolyte layers onto calcium alginate microspheres and drug
aggregate cores is straightforward.

LbL was begun within two hours of microsphere

fabrication, Calcium alginate microspheres were used as an anionic template at neutral
pH, and modified with various PS and PSS for assessment of their affects on DEX
release. The net charge of DEX can be tuned, based on the pH of the solution in which it
is dispersed [69]. Polycations PS and GelB, and polyanions PSS and CS (1-5 mg/mL)
were added to either microsphere suspension or drug aggregates and sonicated for 15-30
minutes to reduce the particle size. The mixtures were then centrifuged at 3000 rpm for 5
minutes to remove any excess unadsorbed polyelectrolyte.

Three centrifugation

washings in deionized water were completed before addition of the complementary PEs
to generate a complete bilayer (either PS/PSS or GelB/CS). The process was again
repeated (without sonication) until the desired layer architecture was achieved (Figure
4.2).

Figure 4.2. Schematic of LbL surface modification of micronized dexamethasone for production of
dexamethasone aggregates.
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4.3 Results and Discussion
4.3.1 Influence of Layer Architecture
on Aggregate Assembly
DEX, a synthetic glucocorticoid, was chosen as the model drug because of its low
cost, anti-inflammatory properties, and use as a mesenchymal stem cell differentiation
factor [69]. The addition of polyelectrolyte layers to micronized DEX was expected to
both solubilize and delay the release of the hydrophobic drug.
The layering scheme chosen was dictated by the isoelectric point (pi) of each
molecule, or the pH at which there is an equal amount of positive and negative charge.
Table 4.1 provides the isoelectric points for the molecules considered for use in the
layering of the drug aggregates and calcium alginate microspheres as detailed in this
chapter.
Table 4.1 Polyelectrolytes, Biomolecules and their Isoelectric Points
MOLECULE
Chondroitin sulfate
Dexamethasone
Gelatin, type A
Gelatin, type B

ABBREVIATION
CS
DEX
GelA
GelB

Pi
3.2-3.5
5
7-9
4.7-5.4

Poly(styrene sulfonate)
Protamine sulfate
Polydiallydiethyl ammonium

PSS
PS
PDDA

2
10-12
12

A number of layering schemes were investigated using ^-potential measurements
to confirm charge reversal, an indication of successful LbL assembly (Table 4.2). It was
hypothesized that oppositely charged constituents which provided the greatest charge
difference with each layer deposition would generate a stiffer capsule, thus slowing
diffusion of the drug core. Those combinations that showed surface charge reversal and
large changes of magnitude for alternating charges were selected for use in further
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experimentation. It is important to note that an additional goal was to use natural or
biocompatible polyelectrolytes, because the systems would be evaluated in cell culture.
Thus, layer architectures employing PDDA and PEI were not analyzed, despite their
strong cationic nature [135].
The shell buildup onto the drug crystals was monitored through quartz crystal
microbalance (QCM) and ^-potential measurements.

Table 4.2 shows the mean C,-

potential readings for ten measurements.
Table 4.2 Layering Schemes and Surface Charge Measurements for Potential Surface
Modifications of Dexamethasone.
SCHEME
A - DEX(PSS/PS)
pH4
B-DEX(PSS/GelA)
pH4
C - DEX(CS/PS)
pH4
D - DEX(CS/GelB)
pH4

LAYER
DEX
DEX/PSS
DEX/PSS/PS
DEX
DEX/PSS
DEX/PSS/GelA
DEX
DEX/CS
DEX/CS/PS
DEX
DEX/CS
DEX/CS/GelB

t-POTENTIAL (mV)
21.62
-50.81
30.66
24.57
-50.43
-43.51
23.60
-10.98
14.10
27.34
-11.93
5.34

As shown in schemes A through D, DEX carries a moderate positive charge at pH
4, which is in agreement with the fact that its isoelectric point is 5. At pH 4, the
adsorption of PSS onto DEX aggregates causes a strong reversal of the surface charge, to
around -50 mV. Given that PSS is a strong polyelectrolyte with pi of 2, a large negative
charge is expected.
In scheme A, adsorption of PS onto the anionic PSS layer causes charge reversal
to a net positive. Considering that the solvent has a pH of 4, relatively far from the
isoelectric point of PS, one would expect a strong positive surface charge. Schemes B
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and D involve the use of gelatins. When working at pH 4, GelA is expected to have a
positive net charge, based on its pi 7-9. As seen from scheme B in Table 4.2, GelA did
not provide the anticipated surface charge reversal when used with anionic PSS. Further
investigation of the ^-potential measurements demonstrates that GelA reduces the
magnitude of surface charge from -50.43 to -43.51 causing it to become less negative. C,potential measurement of GelA at pH 4 in DI H2O reveals that it carries a small positive
charge of 2.23. It is likely that although GelA has a net positive charge under these
conditions, its magnitude is not enough to cause complete surface charge reversal. GelA
is a much bulkier than DEX and PSS; thus there is no indication that the gelatin molecule
cannot "cover" the DEX and PSS molecules during the self-assembly process. In fact,
the bulky nature of gelatin and its ability to swell may interfere with the formation of a
compact monolayer, leading to disorganization or derealization of charge, termed
"charge stripping" [77]. Another explanation may be that the molecules act other than
electrostatically, altering the global charges of the composite layers. Based on these
preliminary results, Schemes A and D were selected for further investigation.
4.3.2

Comparison of PSS/PSModified Release Systems

4.3.2.1 Zeta-potential
measurements
As shown in scheme A, particles were assembled at a pH 4, where DEX is
strongly positive and can be alternated with PSS and PS, which are both strong PEs.
Because these structures were to be tested in a cell culture system, the surface charge
under physiologic conditions at pH 7 was analyzed. DEX, having an isoelectric point of
5, is negative at physiologic pH [69]. The results for ^-potential characterization of layer
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deposition onto DEX aggregates and DEX loaded calcium alginate microspheres
(DLCAMs) are provided in Figures 4.3 and 4.4, respectively.
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Figure 4.3. Net surface charge characteristics following deposition of PSS and PS monolayers onto
dexamethasone aggregates assembled at pH 4 and resuspended at pH 7

Comparison of ^-potential measurements for DEX/(PSS/PS)2

aggregates

assembled at pH 4 and resuspended in pH 7 PBS indicate the poly electrolytes become
less charged under simulated physiologic conditions, indicating a decrease in interlayer
electrostatic attraction and a potential means of drug release (Figure 4.3). Thus, when
aggregates assembled at pH 4 are immersed in pH 7 aqueous solution, such as cell culture
media, the PEs are not as charged, and thus have a tendency to bulk up. Moreover, the
presence of ions, such as those present within PBS and HBSS further contribute to the
bulkiness of the layer architecture. Simply put, the weakened layer interactions induced
by a change in pH likely contribute to drug release. Direct tinplating of DLCAMs with
two bilayers of PS/PSS reveals that the surface charge reverses with deposition of each
layer, demonstrating successful electrostatic assembly (Figure 4.4).
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Figure 4.4. Net surface charge characteristics following deposition of PS and PSS monolayers onto
dexamethasone-loaded calcium alginate microspheres at pH 7.

4.3,2.2 OCM measurements
As a means of determining the mass deposited and layer thickness of each step,
LbL assembly was performed on a silver 9 MHz QCM electrode. After each layer
deposition, the electrode was dried in a stream of N2 and its frequency shift recorded.
The thickness deposited on both sides of the electrode with each adsorption step is
correlated to a decrease in the resonant frequency of the electrode, based on the following
empirically derived relationship [76,108]:
AL = -0.017AF
The

multilayer

architecture

(PSS/PDDA)2/(PSS/DEX)/(PSS/PS)

was

characterized to determine the thickness of the PSS/PS bilayer, where the first five
monolayers were used as precursors (Figure 4.5).
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Figure 4.5. Progressivefilmthickness after deposition of PSS and PS monolayers as obtained
from QCM measurements, n=3.
Precursory layers are essential for subsequent stable film deposition. As shown,
linear film assembly is noted with the addition of each polyelectrolyte layer. The slope of
the line differs for measurements obtained from precursors (first five cycles) and the
active layers of interest. This observation is most notable for the films assembled at pH7.
As shown in Table 4,3, comparison of QCM results obtained at pH 4 and pH 7 reveals
that thicker coatings are obtained at pH7.

Table 4.3 Average Monolayer Thickness for PSS and PS Layers Deposited on
Dexamethasone Aggregates at pH 4 and pH 7
Polyelectrolyte
PSS
PS

Mean Thickness (nm)
pH 4
pH 7
4.15 ±0.17
7.04 ±2.86
3.73±0.29
2.79 ±0.59
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One possible explanation for this observation is that the molecules carry a greater
charge at pH4, as evidenced from the ^-potential data. Given that the charge is greater
under these circumstances, the monolayers are highly attracted to one another, and thus
adopt a more flattened conformation when layered. Immersion of these aggreates in a
pH7 solution, which is closer to the isoelectric point of PS, causes the polyelectrolytes to
assume a bulky conformation.

The electrostatic attraction between the PSS and PS

monolayers is weakened at this pH, and the resulting layers are thicker. An additional
point of observation is that the bilayers generate thicknesses greater than the expected 1-2
nm growth step.

Both the solution pH and the ionic content of PBS are likely

contributors to creating coiled, bulky layers, resulting in large steps of thickness growth.
It is assumed that similar bilayer thicknesses exist for deposition of PS and PSS onto the
calcium alginate cores, thus the buildup of these layers specificially onto calcium alginate
was not studied.
4.3.2.3 Dexamethasone release
testing
The rate of release of DEX from the PSS/PS modified systems was measured in a
Side-bi-Side® diffusion chamber (Permegear, Inc.). This apparatus uses two, 3 mL
chambers (a donor and acceptor), separated by a 0.2 um filter. The temperature was kept
at a constant 35 °C, and the samples were stirred continuously to ensure homogeneity.
For each of the testing setups, samples were collected at regular time intervals and
replaced with fresh PBS of the same volume. The absorbance value for each sample was
determined at 239nm, and converted to concentration, based on a predetermined
calibration curve for DEX.
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The cumulative release profiles obtained from dissolution testing of
unencapsulated DEX, PSS/PS surface-modified DEX (termed: DEX aggregates)
assembled at pH4, and DLCAMs are shown in Figure 4.6. Over a three-hour period,
DEX release was 42%, 48%, and 13%, respectively, for each of the aforementioned
preparations. It can be observed that the addition of PSS/PS bilayers to DEX aggregates
expedites the drug release while inclusion of DEX within the calcium alginate matrix
significantly retards the release rate of the drug.
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Figure 4.6. Release profile for PSS/PS modified DEX aggregates, DEX in alginate microspheres, and
unencapsulated DEX, 3 mg preparations used, release testing in PBS.
A substantial burst release (28%) of DEX is shown for the surface-modified
aggregate system over the first 30 minutes of drug dissolution. Conversely, only about
4% of DEX was released over the first 30 minutes from the calcium alginate
microspheres. The zero-order release kinetics were determined for both drug release
systems (Figure 4.7).
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Figure 4.7. Steady-state release kinetics for dexamethasone aggregates and dexamethasone-loaded
microspheres

Table 4.4 details the encapsulation efficiency of both drug preparations, as well as
the amount of drug release per minute, following the burst phase of drug release. The
polymer to drug ratio for each delivery scheme is provided. Encapsulation efficiencies
were determined by measuring the amount of DEX present in the supernatant after each
centrifugation step.

Table 4.4 Zero-Order Release Kinetics for Dexamethasone Delivery Systems
System
DEX aggregates
DLCAMs

Polymer/drug
ratio (w:w)
0.00023:1
250:1

Encapsulation Release rate
efficiency (%)
mg/min
72.77

0.003

84.14

0.001

Time for complete
drug release (h)
11.86
48.67

About 27% of DEX is lost when the PSS/PS bilayers are directly applied to the
DEX aggregates while only ~16% is lost after application of the same layers onto the
loaded calcium alginate microspheres. The differences in encapsulation efficiency are
attributed to differences in the drug preparations.

With the DLCAMs the drug is

52
physically immobilized, whereas with the DEX aggregates it is simply entrapped
electrostatically. The calcium alginate microspheres release about 1 ug/min, resulting in
a complete drug release over about 48 hours, whereas a release of 3 ug/min and total drug
release time of almost 12 hours is expected for the surface modified DEX aggregates.
Although there is not a large difference in the zero-order release, the small total release
time of the DEX aggregate system can be directly attributed to the 30% burst effect
which occurs initially. A further analysis of the systems indicates that the polymer/drug
ratio for the calcium alginate system far exceeds that of the surface modified DEX
aggregate system, supporting the result of slower release from the alginate. The drug has
a much greater pathlength to travel when encapsulated in alginate, versus being directly
coated with nanothin polyelectrolyte films. Increased dissolution of the PSS/PS modified
DEX aggregates when compared with the unencapsulated DEX is most likely due to
increased motility of the drug. DEX is insoluble in aqueous media; however, adsorption
of water soluble polyelectrolyte layers onto the drug crystals increases their solubility
allowing the solvated DEX to more freely diffuse.
Notably, it may be desirable to have expedited or slowed release of therapeutics
for inclusion in a tissue-engineered product, depending on the application. For example,
expedited release may be warranted for release of an anti-inflammatory agent such as
DEX, immediately after dental implantation to reduce the occurrence of acute periimplantitis. The noted burst effect could be useful for the enhanced delivery of certain
therapeutics, and could be lessened by either application of different polyelectrolytes, a
greater number of polyelectrolyte layers, or a combination of polyelectrolytes that can be
crosslinked. Likewise, slower release of growth factors such as BMPs in an alginate
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matrix may extend the half-lives of these and other biomolecules, allowing them to be
effective over longer time-periods.
4.3.2.4 Confocal microscopy
The geometry and size of the PSS/PS modified DEX aggregates were
characterized through confocal microscopy (Leica TCS SP2, Wetzlar, Germany). For
this application, the terminal layer of PS was tagged with FITC (Appendix B), so that the
resulting architecture deposited onto the DEX core was (PSS/PS/PSS/PS-FITC). Figure
4.8a is an image of several FITC-labeled DEX aggregates, and Figure 4.8b is the
fluorescence intensity profile along a selected DEX aggregate.

I(2.09urn).78.00 1(4.71 Mm)• 103.00 HU27.00 <fc« 2.62um Msx, = 103.00

Figure 4.8. Confocal micrograph and line profile of PSS/PS modified dexamethasone aggregates

From the line profile, the approximate particle size can be directly obtained, and
is 2.62 um, the distance between the two peaks of intensity. Similar measurements of
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other DEX aggregates indicate the average particle size is in the 2-3 um range. It is
widely accepted that polyelectrolyte layers swell significantly in aqueous solution. This
is a possible reason for observation of coatings that are greater than the anticipated 10 nrn
thickness.
4.3.2.5 In vitro analysis of
fibrochondrocvte response
To determine whether the presence of the PSS/PS polyelectrolyte films affected
DEX activity, and whether addition of the layers induced any acute cytotoxic response,
an in vitro culture system was selected.
Cartilage tissue was aseptically excised from the temporomandibular joint (TMJ)
discs of bovine specimens obtained from the Louisiana Tech University abattoir.
Fibrochondrocytes (FCs) from the posterior band were isolated through standard
pronase/collagenase enzymatic digestion and filtration. Primary FC cultures were seeded
at a density of 5 x 106 cell/mL and regularly maintained in Dulbecco's Modified Eagle's
Medium (Mediatech, Herndon, VA) supplemented with 10% fetal calf serum (Hyclone,
Logan, UT) and IX 1% penicillin/streptomycin (Mediatech, Herndon, VA) in 37C, 5%
C02 humidified air. The medium was changed every other day and FCs were passgaed
at 80% confluence using trypsin/EDTA.
Passage four FCs were used for in vitro experimentation. The control group cells
were cultured in the presence of complete culture media only (termed: No DEX). The
two experimental groups were grown in completed media further supplemented with
micronized DEX or PSS/PS surface modified DEX aggregates. Micronized DEX and
surface modified DEX aggregates were added to culture media at 10 nM concentration.
Assessment of cell viability and mitochondrial activity were used as a measure of cellular

55
response to the DEX aggregates.

Furthermore, immunocytochemical analysis for

detection of the extracellular matrix proteins collagen II and aggrecan was performed to
determine whether the augmented release of DEX resulting from the PSS/PS layers
caused alterations in protein regulation.
4.3.2.5.1 Cell viability and morphology
The Live/Dead (Biovision, Mountain View, CA) Assay was used as a measure of
cytotoxic response to the DEX aggregates.

FCs were seeded onto glass coverslips at a

density of 10,000 cells/cm2, supplemented with completed media, and allowed to attach
overnight.

After verifying attachment, the existing media was decanted, and

appropriately supplemented media (DEX or DEX aggregates) was added for each group
of cells. The staining solution was prepared as per the manufacturer's protocol and
incubated for 30 minutes at 37C. Cells were observed using a fluorescent microscope
(Nikon Eclipse TS 100) coupled to a Nikon Digital camera. For each treatment group,
images were acquired at 0, 12, and 36 hours post-media change. Brightfield images were
taken for assessment of changes in cell morphology. Live and dead cells were imaged
using the FITC and TRITC filters, respectively. The numbers of live and dead cells were
quantified using Image Pro Plus software.
Cell viability across all groups was above 90% over the 36-hour experimentation
period. As shown in Figure 4.9, no significant difference in cytotoxicity was noted
between treatment groups at 0 and 12 hours.
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Figure 4.9. Percent cell viability for treated and control cultures, n=3, symbols denote statistically
significant difference, p<05, one-tailed t-test.

At 36 hours, a significant decrease in cell viability was noted for cells
supplemented with DEX and DEX aggregates when compared with controls. However,
there was no significant difference between the two treatment groups at 36 hours. This
observation leads to the conclusion that 10 nM DEX causes a slight cytotoxic response,
but deposition of polyelectrolyte layers does not further affect drug cytotoxicity. In the
literature, no standard concentration of DEX used to differentiate FCs. Rather, a range of
concentrations are used [136, 137]. It is possible mat the cytoxic response is due to a
non-optimal drug concentration either for the cell type or cell density used here. Given
that the range of concentrations is generally 1-100 nM, small variations in concentration
could profoundly affect cytotoxic response and cellular function.
Immediately after the treatment (t=0), each group of cells contains an admixture
of three subpopulations of cells. As can be seen in Figure 4.10 A, D, and G, there are
ovoid shaped, chondroycte-like cells, larger polygonal shaped cells, and spindle-shaped
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fibroblast-like cells within each sample. The latter two subpopulations also have multiple
cellular extensions, which anchor them to the glass substrate. At 12 and 36 hours posttreatment, the control cells (Figure 4,10 B, C) appear to have a similar distribution of the
three subpopulations seen initially.

Figure 4.10. Cell morphology of treated and control cultures at t=0,12, and 36 hours, A-C, controls, D-F,
cells cultured in media supplemented with unencapsulated dexamethasone, G-I, cells cultured in media
supplemented with dexamethasone aggregates. Original magnification 100X, scale bar=15 um.

FCs cultured in media containing 10 nM unencapsulated DEX begin to acquire a
bipolar, elongated shape at 12 hours post-treatment, with most cells having two fillopodia
(Figure 4.10 E). There are still other ovoid, chondrocyte-like cells, and few polygonal
cells having more than twofillopodia!extensions. A similar population of cells can be
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observed for the FCs cultured in the presence of unencapsulated DEX At 36 hours posttreatment. Interestingly, FCs cultured in media containing surface modified DEX appear
to differentiate towards a more chondrocytic phenotype after 36 hours of exposure. This
phenomenon can be observed in Figure 4.10 H and I, where rounded cells in lacunae
comprise the majority of the cell population. Characterization of DEX aggregates in
section 4.3.2.3 of this chapter indicated that release of the drug was expedited when
compared with unencapsulated DEX. Therefore, cells cultured in the presence of
encapsulated DEX are likely exposed to higher local concentrations of DEX when
compared with cells cultured with unencapsulated DEX. It is also important to note that
in preparation of the DEX aggregates, sonication was employed and the drug's particle
size was greatly reduced in comparison to the manufacturer-provided micronized DEX.
For instance, a 30 minute sonication of DEX with the first PE solution caused a particle
size reduction from 1934.1 nm and polydispersity of 0.582 to a mean size of 837.3 nm
and polydispersity of 0.005. This could account for the increased drug dissolution.
There are no noticeable morphological differences between the control FCs (Figure 4.10
A-C) and FCs cultured with micronized DEX (Figure 4.10 D-F), an observation that
further supports the conclusion that the surface modified DEX aggregates induce acute
morphological changes.

Taken together, the results from this study indicate the

possibility for DEX to modulate TMJ fibrochondrocyte phenotypic expression in a
delivery-dependent manner.
4.3.2.5.2 Cellular metabolic activity
FC metabolic activity in the presence of DEX-supplemented media (termed free
DEX) and surface modified DEX aggregates was determined by assessing the cells'

59
ability to convert the tetrazolium salt, WST-1 (EMD Chemicals, Gibbstown, NJ) to a
colored, water soluble formazan product (see Appendix C for a detailed protocol). Only
metabolically active cells can achieve this chemical conversion; thus the mitochondrial
activity is an indirect measure of cellular metabolic activity. Proliferating cells are
generally more active than non-proliferating cells, so this assay can provide some
measure of cellular proliferation based on a standard calibration curve. Although these
types of assays are conventionally used for quantitation of cellular proliferation, it is
somewhat inaccurate to present data in terms of proliferative or viable cell number since
there can be variations between mitochondrial activity within the same cell population
[115]. Therefore, the data in Figure 4.11 are presented as a measure of relative metabolic
activity, normalized to the untreated cells at t=0 hours.
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Figure 4.11. WST-1 Assay for determination of cellular metabolic activity for fibrochondrocytes cultured
in complete media, media supplemented with unencapsulated dexamethasone, and media supplemented
with dexamethasone aggregates. Measurement data obtained at 440nm, reference 690 nm using a Tecan
Spectrophotometer. Seeding density 10,000 cells/well, n=3.

Across all treatment groups, there is a general trend of increasing metabolic
activity of FCs over the 48-hour period. From the results obtained earlier in Section
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4.3.2.5.1 it was determined that DEX aggregates are mildly cytotoxic. The results here
indicate that while there is a difference between the control group and the FCs cultured
with DEX aggregates at 48 hours post-treatment, there is also an increase in metabolic
activity between 36 and 48 hours for both the DEX and DEX aggregates group. These
increases in metabolic activity are less than those noted for the control and could be
attributed to alterations in cellular functionality induced by exposure to DEX.

This

suggests that there is some inhibition of FC metabolic activity from exposure to both
DEX and DEX aggregates. It is possible that DEX aggregates could have a cytostatic
effect on FCs; however, this hypothesis would have to be tested through BrdU analysis.
Differences in metabolic activity can be attributed to the three FC subpopulations
observed earlier in Figure 4.10. Based on the previous analysis of acute FC morphology,
it is reasonable that the control and micronized DEX groups would have comparable
levels of metabolic activity. On a similar note, 36 and 48 hours FCs exposed to DEX
aggregates show less metabolic activity when compared with controls. It is typical to see
reduced metabolic activity or proliferation when differentiation is occurring [138].
Again, metabolic activity can to some degree quantitate the number of proliferating cells,
but other analyses concerning DNA synthesis or biochemical composition would provide
a more complete assessment of cellular response to DEX aggregates.
4.3.2.5.3 Aggrecan and collagen II
immunocytochemistry
FCs were seeded at a density of 20,000 cells/cm and allowed to adhere overnight.
Freshly supplemented media was applied containing micronized DEX or DEX structures.
The cells were washed with HBSS and fixed with 95% ethanol at 0, 12, 24, 36, and 48
hours post-media change. Immunocytochemistry for detection of aggrecan and collagen
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II (mouse monoclonal antibodies) obtained from Calbiochem, LaJolla, CA) was
performed using an anti-mouse/HRP/AEC kit purchased from Spring Biosciences
(Fremont, CA) Staining was performed using diaminobenzidine (DAB) or the HistoMark
ORANGE peroxidase substrate kit (Kirkegaard & Perry Laboratories, Inc., Gaithersburg,
MD) and nuclei were counterstained with either hematoxylin or contrast green. See
Appendix D for a detailed protocol.
To ensure that no nonspecific binding occured, negative controls were performed
by replacing the primary antibodies to aggrecan and collagen II with blocking serum.
Images of the negative controls for aggrecan and collagen II localization in FCs are
shown in Figure 4.12 A and B. FC nuclei are stained green while the remainder of the
cell body is transparent and lacks a brown color, indicating that the secondary antibodies
had no affinity for any endogenous antigens. The results for immunocytochemical
localization of aggrecan for the control, micronized DEX and DEX aggregates group at
t=0 are presented in Figure 4.13.
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Figure 4.12. Negative controls for (a) aggrecan and (b) collagen II. Primary antibodies were replaced with
blocking serum. Original magnification 400X.
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Figure 4.13. Immunocytochemical results for aggrecan localization at t=0 hours (a) control FCs cultured
without dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs
cultured with dexamethasone aggregates.Original magnification 100X.

Figures 4.13 A and B were stained with Histomark Organe and Contrast Green,
and Figure 4.13 C was stained with DAB and Hematoxylin. In each case, there is a
positive reaction for aggrecan in the extracellular matrix, as is evidenced by the light
brown staining outside the nuclei. The presence of various subpopulations of FCs are
also observed, including rounded chondrocyte-like cells, spindle shaped fibrobast-like
cells, and polygonal cells. Figure 4.14 shows aggrecan localization in FC cells at t=12
hours.

c

Figure 4.14. Immunocytochemical results for aggrecan localization at t=12 hours (a) control FCs cultured
without dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs
cultured with dexamethasone aggregates.Original magnification 100X
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As shown in Figure 4.14 A-C, the FCs show a positive reaction for aggrecan, with
those cultured in the presence of micronized DEX having the most intense staining at 12
hours post-treatment (Figure 4.14 B). The other groups (Figure 4.14 A and C) have
markedly less staining. Results for 24 hours post-treatment are shown here in Figure
4.15. The imgaes show aggrecan localization in the extracellular matricies for all groups
of cells. The amount of aggrecan present for FCs cultured without DEX or with DEX
aggregates at 24 hours (Figure 4.15 A and C), appears to similar to that observed for 12
hours (Figure 4.14 A and C). In comparison with Figure 4.14 B (12 hours), aggrecan
production for FCs cultured with micronized DEX has been substantially downregulated
(Figure 4.15 B). In Figure 4.16 aggrecan localization at 24 hours post-treatment is
denoted by the light-brown staining around the nuclei.

Figure 4.17 A-C shows the

results of aggrecan ICC for FCs in each group at 48 hours post-treatment.
Immunoreactivity with aggrecan is noted in each of the images.

Figure 4.15. Immunocytochemical results for aggrecan localization at t=24 hours (a) control FCs cultured
without dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs
cultured with dexamethasone aggregates.Original magnification 100X.
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Figure 4.16. Immunocytochemical results for aggrecan localization at t=36 hours (a) control FCs cultured
without dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs
cultured with dexamethasone aggregates.Original magnification 100X.

Figure 4.17. Immunocytochemical results for aggrecan localization at t=48 hours (a) control FCs cultured
without dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs
cultured with dexamethasone aggregates.Original magnification 100X.
The results of collagen II localization in FCs for each treatment group at t=0 are
shown in Figure 4.18. At this time point each of the samples have approximately equal
intensity staining, indicating similar collagen II content. As shown in Figure 4.19, FCs
without any supplement (Figure 4.19 B) have a higher reactivity for collagen II when
compared with the FCs cultured with micronized DEX and DEX aggregates (Figure 4.19
A and C).

65

Figure 4.18. Immunocytochemical results for collagen II localization at t=0 hours (a) control FCs cultured
without dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs
cultured with dexamethasone aggregates. Original magnification 100X.

Figure 4.19. Immunocytochemical results for collagen II at t=12 hours (a) control FCs cultured without
dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs cultured with
dexamethasone aggregates.Original magnification 100X.

Figure 4.20 depicts collagen II localization for each of the FC groups at 36 hours
post-treatment. It is noted that intense staining is present for the micronized DEX group
(Figure 4.20 B), suggesting that collagen II production has been upregulated since 12
hours. There is medium intensity staining for collagen II in the unsupplemented FC
cultures (Figure 4.20 A) and a smaller amount of collagen II present in FCs supplemented
with DEX aggregates (Figure 4.20 C).
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Figure 4.20. Immunocytochemical results for collagen II at t=36 hours (a) control FCs cultured without
dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs cultured with
dexamethasone aggregates.Original magnification 200X.

Collagen II staining at 48 hours post-media change is shown in Figure 4.21. It
may be observed that the FCs supplemented with micronized DEX (Figure 4.21 B) have
the least amout of staining when compared with the other treatment groups (Figure 4.21
A and C) at this sample point.

Figure 4.21. Immunocytochemical results for collagen II at t=48 hours (a) control FCs cultured without
dexamethasone supplement, (b) FCs cultured with unencapsulated dexamethasone, (c) FCs cultured with
dexamethasone aggregates.Original magnification 200X.
Bom aggrecan and collagen II immunoreactivity was readily apparent in the ECM
of FCs cultured under each of the experimental conditions. One significant finding was
that aggrecan content was nearly constant over the 48-hour experimental period for
unsupplemented FCs and FCs supplemented with the surface modified DEX aggregates.
Aggrecan immunoreactivity was strongly positive at 12 hours and then returned to a
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baseline level at 24 hours for FCs exposed to micronized DEX. This was the only
treatment group for which variation in aggrecan content could be qualitiatively
determined. One possible explanation for the observed peak in aggrecan production at 12
hours is the amount of DEX available for the cells to uptake. In comparison to the
surface modified DEX aggregates, the micronized DEX dissolves more slowly. Notably,
the amount of DEX delivered to the cells in micronized form could have been received in
an irregular manner, due to the noted burst release in the first 30 minutes. It is likely that
the difference in DEX delivery methods and delivery rates led to the differential aggrecan
expression. Similar levels of aggrecan staining for the unsupplemented FCs and the FCs
supplemented with DEX aggregates over the 48-hour period could be attributed to the
quick release of DEX from PSS/PS bilayers. DEX could be loosing its bioactivity early
on before the cells can respond, or the expedited release of DEX could have a delayed
affect on cellular behavior that was not seen in the 48 hour time span.
The data show that collagen II immunoreactivity peaked at 36 hours posttreatment. For the FCs not supplemented with any form of DEX, the weakest reactivity
for collagen II occurred at the t=0 time point. The collagen slides for t=24 hours had to
be discarded due to errors with the staining protocol, thus there are no results for that
time point. In analyzing the ICC results, one must take into account several possibilities.
The cell culture medium was not decanted and replaced during the 48-hour time frame.
Therefore, at some point the DEX could have lost it potency, given that it has a half life
of around 48 hours [139], Last, it has been well documented that cell seeding density can
affect phenotypic expression. This notion could very well explain inconsistencies in
morphological results when compared with Section 4.3.2.5.1.
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Aggrecan and collagen II were used as markers of fibrocartilaginous matrix
characteristics in the bovine TMJ disc, as they are the predominant ECM proteins found
in cartilage [140]. In situ, collagen II is used to resist compression forces while aggrecan
is a critical component of cartilaginous tissues. The immunocytochemical staining for
ECM these markers were analysed on a qualitative basis only. In many cases, the results
were difficult to interpret and compare because the images were not acquired under the
same illumination. Collagen I as well other markers such as vimentin and a-smooth
muscle actin have been differentially expressed in TMJ samples from various species
[140, 141]. It would certainly be helpful to test for the presence of these and other
molecules to fully characterize and detail changes in phenotypic expression concerning
the plasticity of TMJ disc cells. In addition, further long-term, quantititive analyses
should be done to better gauge the effect of DEX aggregates on FC behavior.
4.3.3 Comparison of CS/GelBModified Release Systems
DEX aggregates and microspheres were prepared in a similar manner as described
previously, however, two different PEs were selected for surface modification. GelB and
CS were used as counterions for LbL assembly. The ^-potential measurements for the
assembly of thin films onto micronized DEX and DEX-loaded calcium alginate
microspheres are presented in Figure 4.22. At pH 7, the negative templates have a
surface potential of —15 mV. The addition of the GelB layer confers the surface
positively charged, having a ^-potential measurement of ~+10 mV. Deposition of
alternately charged CS reverses the charge, forming a negative surface. The CS layers
are weakly charged with surface potentials around -5 mV.
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Figure 4.22. Net surface charge characteristics following deposition of CS and GelB monolayers onto
dexamethasone aggregates and dexamethasone-loaded calcium alginate mircopsheres, n=7.

4.3.3.1 OCM measurements
Film buildup onto QCM electrodes was accomplished as previously described.
The results for quantitation of CS and GelB bilayers are presented in Figure 4.23.
Precursory layers of (PSS/PDDA)3 were used before deposition of the layers of interest.
Each CS growth step is roughly 1.5 nm in thickness while GelB layers are nearly 10 nm
thick. The molecular weights of CS and GelB are 60 and 50 kDa, respectively. Larger
growth steps are allowable for GelB deposition steps since the molecule is a hydrogel and
is able to bind water [69].
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Figure 4.23. Progressive film thickness following deposition of CS and GelB monolayers, n=3.
4.3.3.2 Dexamethasone release testing
The release proflie for DEX from DEX aggregates and DLCAMs modified with
two bilayers of GelB/CS is provided in Figure 4.24. Over a seven-hour timeframe, DEX
aggregates release approximately twice as much drug when compared with the DLCAMs.
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Figure 4.24. Release profile for GelB/CS modified dexamethasone aggregates and dexamethasone loaded
calcium alginate microspheres. 50 m g initially incorporated into each drug formulation, n=3.
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GelB/CS modified DEX aggregates release roughly 2% of the drug after 420
minutes of testing while the surface modified DLCAMs release approximately 1%. The
DEX aggregates follow a near linear release profile over the testing period, however, it is
possible that the system is still undergoing burst release, and that the profile shown here
is not the steady-state behavior of the system. The particle size reduction as a result of the
sonication step in combination with the thin layer barrier likely contribute to expeditied
DEX release from the surface modified aggregate systems when compared with the
alginate microspheres.
The release behavior of DEX from the microsphere preparations is biphasic,
having two distinct release profiles. The burst release of DEX from the microsphere
preparations occurs over the first 300 minutes of dissolution. The steady-state behavior
of the system is presented in Figure 4.25.
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Figure 4.25. Steady state release kinetics for dexamethasone loaded calcium alginate microspheres
modified with GelB and CS layers. These resultsshow the amount of dexamethasone released in the linear
phase, the burst phase is removed.

The zero-order behavior of the GelB/CS modified DLCAMs shows a release rate
of 3 ng/min, having a theoretical release time of 114 days, or nearly four months. The in
vitro behavior of this system would have be tested to verify these results. The results in
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this portion of the study were not compared with unencapsulated DEX, however, use of
non-linear PE layers, such as gelatin, onto DEX aggregates has been shown to
significantly retard the release of DEX, when compared with enhanced release typical
from aggregates modified with smaller PEs [69].
4.4 Conclusions
In this work, the LbL fabrication technique was used to assemble nanothin
biocompatible layers onto DEX aggregates and DLCAMs (calcium alginate microspheres
containing DEX). The acute in vitro response of bovine TMJ fibrochondrocytes to the
DEX aggregates was established, whereby exposure to DEX in the surface-modified form
causes differentiation toward the chondrocyte phenotype after 36 hours. In terms of
collagen II and aggrecan immunoreactivity, a transient repsonse to the DEX aggregates
was noted, indicating that protein production can be modulated based on the delivery
mechanism. Moreover, comparisons of the DEX aggregates with DLCAMs showed
expedited DEX release, both when modified with bilayers of PS and PSS or CS and
GelB. A higher encapsulation efficiency and lenghtier drug release time was noted with
DLCAMs. However, the drug loading of the DEX aggregaates is over 1000 times greater
than that of the DLCAMs, and can certainly be advantageous when fabrication costs are
considered.

The in vivo cell characterization results are quite promising, in that the

fibrochondrocytes can be encouraged to assume a different phenotype. Given the results
from cell culture, this system could be implemented or used in conjunction with a TMJ
disc implant for control of associated inflammation as well as cell morphology and
protein expression. However, fibrochondrocyte response in this work was limited to a
period of 48 hours. Future work should investigate the response of other maturation
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states (passages), as well as this and other cell types such as progenitor populations to
both the aggregates and microspheres over the long term, in the context of protein
production, morphology, and biochemical composition.

Moreover,

the precise

mechanisms involved in drug release from each of the preparations is unkown. The
promise of extended release over a four-month period was demonstrated by incorporating
of 50 mg of DEX into the clacium alginate microsphere preparation; however, it is
unknown if the drug can retain its potency for such a time period.

Additional

characterization of the systems concerning structure, geometry, chemical makeup would
be helpful in uncovering their degredation properties over the course of their use, and is
critical for clinical implementation. Similarly, protein interactions with the surfaces are
an important indicator of in vivo behavior.
Key questions still remain to be answered; however, the results demonstrate the
potential for LbL surface modification as a means of controlling the delivery of proteins,
biomolecules and other therapeutics within a tissue-engineered construct while retaining
biological activity. The use of this technology for incorporation therapeutics within a
scaffolding system is presented in Chapter 5.

CHAPTER 5
FABRICATION AND CHARACTERIZATION OF
CELL-SUPPORTIVE SUBSTRATES USING
NEBULIZED LAYER-BY-LAYER
ASSEMBLY
5.1 Introduction
Successful in vitro tissue engineering strategies must account for the reproduction
of the native tissue's microenvironment.

The dynamic cellular microenvironment

requires deployment of growth factors in a controlled manner to initiate, assemble, and
maintain proper tissue architecture [142, 143]. In vivo, a host of growth factors including
TGFPs, BMPs, VEGF, and FGFs play a critical role in cellular maturation, matrix
deposition, and associated protein synthesis [23,142,144-146]. In particular, BMPs have
a marked influence on the morphogenesis of progenitor stem-like cells into mature cells.
In vitro regulation of these molecules offers a significant challenge, given that growth
factors have short half lives and diffuse rapidly from their point of origin [147]. For
example, the growth factor BMP2 is rapidly degraded in vivo by extracellular body fluids,
having a half-life of 7-16 minutes [23, 86,148].
In a clinical setting, regulation of an effective concentration requires intermittent
addition of the therapeutic molecule at the desired site via injections or infusion, which
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can be especially uncomfortable to the patient.

Furthermore, administration of

supraphysiologic amounts of growth factors is expensive, can lead to systemic toxicity,
and have the potentiality cause the proteins to behave as prooncogenes [23].
Strategically assembled multilayer scaffolds offer much potential in creating an
optimal cellular microenvironment which can incorporate necessary proteins, growth
factors and other biomolecules. Since its inception in 1992, layer by layer assembly
(LbL) has been exploited for a number of purposes, including the design of electronic,
optical, and biological systems [72, 149, 150]. Fabrication of nano-organized thin films
via LbL is accomplished through sequential deposition of oppositely charged
polyelectrolytes (PEs) onto a charged template. Traditionally, the substrate is immersed
in a PE solution of opposite charge allowing for surface charge reversal, and then rinsed
to remove any unbound PE. Subsequently, the newly charged surface undergoes the
same process. The cycle of immersion in an oppositely charged PE followed by rinsing
in water is repeated until the desired layer architecture has been reached. The steadystate adsorption of PEs onto a charged substrate is the rate-limiting step for the LbL
technique. Traditionally, it is necessary to allow a deposition time of up to 20 minutes
for each PE layer, followed by several rinses in pure water at 5-10 minutes each [151].
Recently, methods for expeditious fabrication of electrostatically organized thin-films
have been described using aerosol spraying. Spraying of PEs onto substrates significantly
reduces the required PE contact time while maintaining similar layer characteristics as
conventional substrate dipping [150, 151].

To expand upon these recent efforts,

ultrasonic nebulization was explored as a tool for creating multilayered, multicomponent
assemblies.
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This work combines the principles of electrostatic layer-by-layer nanoassembly
with ultrasonic nebulization for expedited layer fabrication. Efforts in our lab have been
directed towards the use of nebulization to create biocompatible substrates for a variety
of tissue engineering applications. In our previous works multilayer architectures
functionalized with active layers of protamine sulfate (PS), chitosan (CHI), and
chondroitin sulfate (CS) were fabricated using nebulization. Mist distances of 1.5 or 3.0
cm generated films up to twice the thickness achieved from dipping when polyelectrolyte
concentrations between 3-5 mg/mL were used. An additional observation noted in the
case of nebulized films was the evenly distributed surface, as demonstrated through AFM
studies.

Moreover, mouse mesenchymal stem cells (MSCs) showed preferential

attachment to the nebulized substrates over a two-day period when compared with
similarly organized dipped substrates.

These preliminary results demonstrated the

potential to create superior cellular microenvironments through nebulization [85].
The work detailed herein extends our past efforts to include analysis of
nanoparticle- and growth factor-embedded nebulized nanofilms.

Nebulized films

comprised of Ti02, a material widely used in orthopedic and dental implants were
produced. Similar films were also fabricated containing TGF(3i, a potent growth factor
implicated in the wound-healing process. Film growth was monitor using the QCM
method, and surface topography was imaged with AFM. The results demonstrate that
varying surface morphologies of dense, nanoscale organization can be created using
nebulization for production of LbL films.
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5.2 Materials and Methods
5.2.1

Preparation of Polyelectrolyte.
Nanoparticle, Protein,
and Drug Solutions
For this work, materials suitable for LbL assembly were selected. Those chosen

include traditional PEs with charged functional groups, charged colloidal nanoparticles,
and water soluble proteins. The PEs poly(dimeththyldially ammonium chloride), 20%
(PDDA MW 400,000) and poly (styrene sulfonate) sodium salt, 30% (PSS) were
purchased from Sigma Aldrich and prepared in sterile deionized water (DI H2O) at a
concentration of 3 mg/mL. Titanium Dioxide (P25 Degussa AG, Germany) diameter ~21
run, was prepared in DI H2O at a concentration of 6 mg/mL and adjusted to pH 4 with
dilute HC1. A stock solution of 0.4 mg/mL Dexamethasone (MW 392.46, Sigma) was
prepared in DI H2O and further diluted in either cell culture media or DI H2O to give a
final concentration of 10 nM. Growth factors were prepared according to the supplier's
recommendations. Briefly, 1 ug of TGF(3i (ProSpec, Israel) was reconstituted in 4 mM
HC1 containing 1 mg/mL of Bovine Serum Albumin (Sigma) to yield a stock solution of
1 ug/mL. The growth factor stock solutions were then diluted with either cell culture
medium or buffer, as appropriate for experimental use, to give a final concentration of
lOng/mL. Table 5.1 details the molecules used and their associated isoelectric points.

Table 5.1 Isoelectric Points of Polyelectrolytes, Nanoparticles, and Biomolecules
MOLECULE
Dexamethasone
Poly(styrene sulfonate)
Poly(dimeththyldially ammonium chloride)
Protamine Sulfate
Titanium Dioxide
Transforming Growth Factor Beta-1

ABBREVIATION
DEX
PSS
PDDA
PS
Ti0 2
TGFPJ

PI
5
2
12
10-12
5
8.9
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5.2.2 Fabrication of Multilavered
Substrates
Glass slides (VWR) were first immersed overnight in 70% isopropyl alcohol
(IPA). They were then cleaned by sonication in 70% IPA for 20 minutes and allowed to
air dry. An ultrasonic nebulizer (SigmaNeb) was used to deposit various 14-layered
architectures onto the negatively charged slides. To carry out the assembly process, ~3
mL of PE, nanoparticle, or drug solution was placed in the nebulizing chamber. The
glass substrates were sprayed with the appropriate solution for varied times and mist
distances. When indicated, substrates were rinsed between layer cycles by 30 seconds of
nebulization in DIH2O. As illustrated in Figure 5.1, layers were deposited by vertically
orienting glass substrates so that the receiving surface was perpendicular to the nebulizer
output. The orientation of the substrate in this manner allows for maximal drainage of
the solution runoff [151]. Three bilayers of (PDDA/PSS) were deposited as a precursory
foundation for further layer assembly.

Charged Molecules/Particles
Glass
'Substrate
Output
Tubing

Mist Distance

X

Excess Runoff

Figure 5.1. Diagram of experimental setup for LbLfilmdeposition by nebulization.
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An important facet of this work was the evaluation of how various deposition
parameters affected film properties, before use for in vitro testing. An initial set of
experiments was performed in which LbL films comprised of PEs and polymers were
assembled while individually varying nebulization parameters and the resulting films
were analyzed for thickness and surface morphology. The results of these preliminary
experiments are provided in Table 5.2. The deposition parameters selected for further
experimentation was based on these findings.
Table 5.2 Qualitative Outcome of Varying Individual Nebulization Parameters for LbL
Films Composed of Synthetic and Natural PEs.
PARAMETER

Range

Qualitative change over parameter range

Solution concentration (mg/mL)

3-5

No noticeable trend

Regulator output (intensity)

Min-Max

Increase in thickness

Mist distance (cm)

1.5-3.0

Decrease in thickness
Decrease in surface clustering and
aggregation (density)

Mist time (sec)

30-180

Increase in surface clustering and aggregation
(density)

Rinse time (sec)

0-30

No effect

The polyelectrolytes PSS, PEI, CS, and PS were used to generate 14- or 15layered multiassemblies. In general, there was no noticeable trend in thickness change
for solution concentrations between 3 and 5 mg/mL as measured with QCM. In some
instances, concentrations of 3 mg/mL yielded higher film thicknesses than those
assembled using 5 mg/mL. In other situations, the exact opposite was observed. Most
likely, the chemical composition of the substance has some influence, and solution
concentration alone had no significant effect on film thickness.
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The regulator output was dialed to the maximum position for generation of the
thickest films within a specified time frame. Conversely, film deposition performed
when the regulator output was at the minimum setting resulted in thinner films. A mist
distance of 1.5 cm generated slightly larger film thickness than those assembled using a
mist distance of 3.0 cm. The higher film thickness at 1.5 cm, however, was also met
with a higher level of particle clustering and aggregation when compared with those films
whose surface was 3.0 cm away from the nebulizer output. These observations raise the
issue of a tradeoff between film thickness and film density. It was assumed that film
density could possibly be adjusted by fine-tuning the concentrations of each PE, however,
this was outside the scope of the current work. Increasing the mist time from 30 sec to
180 sec led to an increase in clustering and aggregation. Rinsing of the substrate was
found to be unnecessary, most likely because any loosely adhered moieties are simply
removed in vertical run offfromthe surface.
Based on these results, it was determined that suitable LbL assembly via
nebulization could be achieved using a mist distance of 3.0 cm, and a deposition time of
30 sec without rinsing between layers. The regulator was kept at the maximum setting,
and the PE concentration was used within a range of 3-5 mg/mL.
5.3 Results and Discussion
5

-3.1 LbL Nebulized Thin Films
Functionalized with TiOi
and Dexamethasone
Four layering schemes were identified for characterization and testing. The glass

substrates were assembled so that each contained one layer of DEX and alternating layers
of Ti02 nanoparticles with PSS. The specific architectures along with the nebulization
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parameters used for film fabrication are summarized in Table 5.3. In each case, the
layers were sprayed for 30 seconds at a distance of 3 cm from the substrate. The
substrates were rinsed after deposition of each layer. The first architecture,
(Ti02/DEX)/(Ti02/PSS)3 was assembled onto the precursory (PDDA/PSS)3 nebulized
films. In an identical manner, a film with architecture (Ti02/PSS)3/(Ti02/DEX) was
deposited onto the precursory layers. These films were created for comparison of DEX
release, as the first film contained DEX near the bottom of the film (D-DEX) and the
latter contained DEX in a superficial position within the film (SF-DEX). Similar films of
architecture (Ti02/DEX)/(Ti02/PSS)3/TiC>2 and (Ti02/PSS)3/(Ti02/ DEX)/Ti02, termed
DEX-D-Ti02, and DEX-SF- Ti0 2j respectively, were also fabricated to determine the
effect of adding a terminal layer of Ti0 2 . The materials characterization and comparison
of these films with conventional dipping are included in this section.

Table 5.3 Layering Architectures for Nebulized Films Functionalized with Ti0 2 and
Dexamethasone.
SCHEME

ARCHITECTURE

DEX-D
DEX-SF
DEX-D-Ti02
DEX-SF-Ti02

(PDDA/PSS)3/(Ti02/DEX)/(Ti02/PSS)3
(PDDA/PSS)3/(Ti02/PSS)3/(Ti02/ DEX)
(PDDA/PSS)3/(Ti02/DEX)/(Ti02/PSS)3/Ti02
(PDDA/PSS)3/(Ti02/PSS)3/(Ti02/DEX)/Ti02

5.3.1.1 Zeta-potential
measurements
Thin film surface charge and layer interactions were studied through ^-potential
measurements (Zetapulus Zetasizer).

Anionic polybead carboxylate microspheres

(Polysciences Inc.) of diameter 450 nm were prepared at a concentration of 10 mg/mL.
The desired layering scheme was achieved by immersing the microsphere solution in the
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nanoparticles, drag, or polyelectrolytes for ten minutes in a sequential fashion.
Following deposition of each layer, the microspheres were rinsed thrice in DI H20 by
centrifugation at 5000 RPM for five minutes. The net surface charge characteristics for
tiie nebulized films embedded with Ti02 and DEX are presented in Figure 5.2.

Deposited Layer

Figure 5.2. Net surface charge characteristics following deposition of thin films comprised of Ti02 and
PSS firactionalized with dexamethasone (•) as a superficial layer and (•) as a deep layer, n=10.

The first six layer cycles shown are the precursory layers. The potential of the
first PDDA layer is ~ +30 mV. After deposition of PSS, the surface is negatively charged
(~ -20 mV). With each additional layer, there is charge alternation from positive to
negative. The noted charge reversal is an indication of overcompensation of the previous
charge and indirect verification of film growth. One can notice that when DEX is
embedded deep within the film, the surface charge at that layer is ~ -20 mV. When that
same layer is replaced with PSS, the surface charge carries a larger magnitude of ~ -30
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mV. In a similar manner, inclusion of DEX as a superficial layer results in a surface
charge of ~ -20 mV and replacement of that layer with PSS yields a surface potential of ~
-50 mV. The TiCh nanoparticle layers stabilize around +25 mV, with terminating layers
of+18 mV for DEX-D films and +33 for DEX-SF films.
5.3.1.2 QCM measurements
For the purpose of monitoring film buildup, silver electrode QCM crystals
(Supplier) with a 9 MH resonant frequency were used as substrates. After immersion in
or spraying of the appropriate solution, the crystal was dried in a stream of N2. The
frequency shift after deposition of each layer was monitored and correlated to a change in
thickness. The comparison of film thicknesses generated by dipping and nebulization for
the architecture (PDDA/PSS)3/(Ti02/DEX)/(Ti02/PSS)3/Ti02) is provided in Figure 5.3.
140
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Figure 5.3. Progressive film thickness for (PDDA/PSS)3/(Ti02/DEX)/(Ti02/PSS)3-Ti02 generated by
dipping ( • ) and nebulization (•), n=3.
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The film growth for the precursory layers is small for both the nebulization and
dipping methods, owing to the fact that there is inhomogeneous charge density on the
substrate surface with these initial layers. The dipping process produces a precursory
thickness of 9.613 nm, when compared with 4.131 nm for those produced by nebulization
of the same layer configuration. A bi-phasic linear increase in film thickness is noted for
both film preparation methods. The total thickness generated from dipping is 117.419
nm while nebulization produces a total film thickness of 37.417 nm. For the film
produced by dipping, the first TiC>2 nanoparticle layer measures around 20 nm, however,
the subsequent layers measure around 10 nm, about half the particle size. The difference
in thickness between the first and successive TiC>2 layers is attributed to packing and
interconnectivity of the PE layers with those of the nanoparticles [152]. The even further
reduced layer thickness (~ 5nm) for TiC>2 produced by nebulization could be due to the
fabrication procedure. Conceivably, the ultrasonic pulses induce particle size reduction.
For this film configuration, DEX is located near the bottom of the film. The
approximate monolayer thickness for DEX is around 2 nm for nebulization, and around
0.5 nm for the dipping method. The small thickness of the DEX monolayer generated by
dipping is attributed to two possibilities. First, the previous TiC>2 layer could have
facilitated loss of DEX subsequent to the rinses in water. Additionally, a lengthier
deposition time may have been necessary for the optimal thermodynamic stability to be
achieved. It is well understood that drugs, proteins, and polypeptides assume much more
complex molecular configurations than polyelectrolytes, and thus their adsorption
kinetics differ greatly [153].
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Similar precursory coatings of three bilayers of PDDA/PSS were used in the
second layer architecture, however DEX was incorporated near the surface of the
composite film, so that the configuration was (PDDA/PSS)3/(Ti02/PSS)3/(Ti02/DEX)T1O2. As shown in Figure 5.4, the precursory layers follow a linear trend with deposition
of each layer.

PDDA PSS PDDA PSS PDDA PSS Ti02 PSS Ti02 PSS Ti02 PSS Ti02 DEX Ti02
Depositited Layer

Figure 5.4. Progressivefilmthickness for (PDDA/PSS)3/(Ti02/PSS)3/(Ti02/DEX)-Ti02 generated by
dipping (•) and nebulization (•). Inset shows precursory layers for both methods, n=3.
The cumulative precursory layer thicknesses generated by nebulization and
dipping are 6.71 nm and 6.57 nm, respectively. An increase in the slope of film growth is
noted with addition of the TiC>2 nanoparticle layer for both preparations, however, the
T1O2 layer is much thicker when the conventional dipping method is employed. The
cumulative thickness achieved with dipping is 114.07 nm while mat achieved through
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nebulization is 43.04 nm. The average layer thicknesses produced by both the dipping
and nebulization techniques are elaborated below in Table 5.4.

Table 5.4 Average Layer Thicknesses Produced by Dipping and Nebulization.
LAYER
Ti02
Ti02/PSS
DEX

THICKNESS (nm)
Dipping

Nebulization

20.6 ± 2.39
21.2 ±2.31
0.63 ±0.18

6.11±0.65
7.75 ± 0.71
1.78 ±0.73

The data in Table 5.4 show that on average, nebulization produces smaller TiC>2
nanoparticle layers and larger DEX layers when compared with those generated using the
conventional dipping process. For each bilayer, the PE/PE pairs create thinner layers
than the Ti02/PE pairs.

This phenomenon is easily explained, given that the

nanoparticles are rigid and have fixed dimensions. In comparison, polyelectrolytes are
pliable and can adsorb electrostatically to achieve a thermodynamic minimum. It is thus
noted that the thickness of the layers is largely dependent on the incorporation of Ti(>2
nanoparticles. As stated earlier, smaller T1O2 layers are likely produced because the
energy of the ultrasonic pulses breaks the nanoparticles up into smaller pieces. One way
to verify this would be to comparing particle sizes of the drug as received from the
supplier and after ultrasonication. The DEX layers produced by nebulization could be
larger than those produced by dipping because of the chemical composition, charge
density, or some other underlying phenomenon. Under the deposition conditions used, the
TiC>2 and DEX are moderately charged (based on -potential and considering their
isoelectric points). Particle aggregation of TiCb is another possibility, which resulted in
the large growth steps for dipping as observed in Figure 5.4.

Moreover, the weak
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interfacial attraction between the nanoparticle and polyelectrolyte moieties could also
account for the large growth steps seen here. For a final comment, the nanoparticle and
drug solutions were prepared in different pH solutions, and it is unknown what effect this
may have had on the layer adsorption kinetics.
In the current available literature there exist some inconsistencies surrounding
whether sprayed films are thicker than those produced by the conventional dipping
method [150, 151]. In our previous works using nebulization we demonstrated that
thicker films could be obtained when compared with the conventional substrate dipping
method [85]. Izquierdo showed that sprayed and dipped films had the similar film
thicknesses, where the only difference was the amount of time required to build the films.
In this work it was also demonstrated that through use of longer spraying times, thicker
films could be generated. It is the opinion of this author that films of varying thicknesses
(equivalent to, thicker than or thinner than those achieved by dipping) can be produced
depending on the spraying technique (aerosol vs. nebulization), film composition, and
ionic strength of the solutions, among other possible factors. The mechanisms by which
nanoparticles interact with the nebulization or aerosol machinery are likely very different
than the way in which proteins or simple polyelectrolyes are expelled from the same.
5.3.1.3 AFM measurements
A Quesant Q-Force AFM operated in non-contact mode was used to assess the
topography of the various films fabricated on glass slides. For each sample, a scan area
of 40 x 40 um was imaged. In some instances, smaller areas were desired.

Typical

images were obtained using a scan rate of 1-2 Hz. A histogram analysis was performed
for each film architecture, to obtain values for roughness parameters.

Several
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measurements of island (particle) size were determined by dimensional analysis available
through the AFM software. Other aspects of the physical film characteristics were noted.
An AFM image of the nebulized film architecture (PDDA/PSS)3/(Ti02/DEX)/
(Ti02/PSS)3/Ti02, is shown in Figure 5.5.

Figure 5.5. Non-contact AFM scan for nebulized architecture
(PDDA/PSS)3/(Ti02/DEX)/(Ti02/PSS)3/Ti02. Scan area is 30x30 um2. (a) 3-D topographical
representation (b) slope shading
As seen in this image, the film has a number of rounded surface features which
are roughly similar in size. These clusters have an approximately uniform size of lum in
the x and y directions while the height in the z-direction is around 100 nm. There is some
particle aggregation, denoted by the large ~lum high feature. The underlying film
surface is relatively smooth and even. The parallel striations on the surface (5.5 a) are an
artifact from the AFM cantilever tip, and do not accurately reflect the film's surface
topography. The film configuration (PDDA/PSS)3/(Ti02/PSS)3/(Ti02/ DEX)-Ti02 in
which there is a superficial layer of DEX, terminated with a layer of Ti02is shown below
in Figure 5.6.
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Figure 5.6. Non-contact AFM scan for nebulized architecture
(PDDA/PSS)3/(Ti02/PSS)3/(TiCy DEX) /Ti02.15x15 um2 scan area (a) 3-D rendering, (b) slope shading

ITiisfilmhas a fairly homogeneous granular background (Figure 5.6 b), with
some larger clusters and aggregates protrudingfromthe surface. The average cluster size
was 941 nm across, with some of the features exceeding 2 um. The cluster heights range
from around 75-285 nm. Figure 5.7 represents a typical surface scan of film configuration
(PDDA/PSSy (Ti02/DEX)/(Ti02/PSS)3, where DEX is near the bottom of thefilmand
the terminal layer is PSS.

Figure 5.7. Non-contact AFM scan for nebulized architecture (PDDA/PSS)3/(Ti02/DEX)/(Ti02/PSS)3,
15x15 um2 scan area (a) 3-D rendering, (b) slope shading.
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The film's surface has several clusters within the substrate plane. The clusters are
here have flattened plateaus, much different than the sharply pointed clusters seen in
Figure 5.6. Also in there are concentric steps in the background of thefilm,probably due
to pulsation of the nebulizer output. Figure 5.8 shows a typical AFM images for the film
(PDDA/PSS)3/(Ti02/PSS)3/ (Ti(V DEX), in which there is a terminal layer of DEX.

Figure 5.8. Non-contact AFM scan for nebulized architecture (PDDA/PSSyCTiCVPSSMTKV DEX).
5x5 urn2 scan area (a) 3-D rendering, (b) slope shading.

When compared with the other threefilms,this one has a much finer structure and
very closely packed features. This surface also appears to be rougher than the others, but
one must take into consideration that the scan area is much smaller than that of the other
images.
Overall, the nebulized films have a certain degree of regularity, with the clusters
within a specific film configuration assuming similar geometries. It is important to note,
however, that the nebulization process can generate irregular film densities in areas not
directly perpendicular to the output tubing. The morphology of a PSS-terminated film is
different from mat of a Ti02- or DEX-terminated surface. This result is not surprising
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since PEs such as PSS are typically more flexible when compared with more complex
moieties such as drugs and inorganic nanoparticles. Generally, polyelectrolytes can
arrange themselves into more stable films. Taking the AFM results together, addition of
a terminal layer of T1O2 appears to make the surface smoother, perhaps by covering the
underlying grains. The PE layers are probably coating the previous TiC>2 NPs in such a
way that the NP features are not distorted. It would be of interest to image the surface at
each step during the film buildup process to confirm the inferences made here.
The size of clusters and surface domain features were obtained from surface
section line profiles. Table 5.5 provides a summary of the data acquired from AFM
measurements, including the average film height, feature sizes, and 3-D delta A, a
software generated measure of surface roughness in the x-, y-, and z-directions.
Table 5.5 Surface Parameters for Nebulized Ti02 Films Obtained from AFM
Measurements
SCHEME

Average thickness
(nm)

Feature size (nm)
n=3

3-D Delta A

DEX-D
DEX-SF
DEX D-Ti02
DEX SF-Ti02

63.872 ±6.804
27.643 ± 5.065
301.94 ±46.89
68.312 ±7.634

1044.00 ±96.804
707.66 ±22.481
870.07 ±33.559
941.28 ±59.833

0.1073
0.0338
0.6797
0.1652

The films terminated with Ti02 nanoparticles are thicker than their counterparts
that are not terminated with Ti02. The cluster sizes generated from nebulization are
between 0 .7-. 1.0 um in the substrate plane. These particle sizes are on the lower end of
the reported values for a typical nebulizer output [113]. The 3-D delta A, which is a
measure of film roughness is directly proportional to film thickness. That is, those films
with the largest thickness also have the largest roughness in 3-dimensions. This result is
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in agreement with other works, which have shown the trend of increased surface
roughness with increasing layer thickness [90].
5.3.2 LbL Nebulized Thin Films
Functionalized with TGFfy
Multilayered films were assembled on glass substrates in the manner described in
section 5.2.2. Transforming growth factor-beta (TGFf3i) was incorporated as an active
component in either deep (D), double layered (DL), or superficial (SF) 14-layer film
architectures [92]. Table 5.6 provides a description of each scheme. The materials
characterization and cellular response associated with these films are detailed in this
section.
Table 5.6 Nebulized Layer Architectures Functionalized with TGF|3i
SCHEME

ARCHITECTURE

D
DL
SF

(PDDA/PSS)3/(PDDA/TGFPi)/(PDDA/PSS)3
(PDDA/PSS)3/(PDDA/TGFp1)4
(PDDA/PSS)6/(PDDA/TGFpO

5.3.2.1 Zeta-potential measurements
Each layer scheme was built up on anionic microspheres in the manner as
previously described. Three precursory bilayers of PDDA/PSS were used to establish a
foundation of uniform charge density for proper LbL fabrication of the layers of interest.
As shown in Figure 5.9, the first six layer cycles for each scheme have nearly identical C,potential values, where the PDDA layers are strongly positive, and the PSS layers are
moderately negative.
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Figure 5.9. Zeta-potential alterations for nebulizedfilmswith TGFpi-embedded in deep, double-layered,
and superficial modalities, pH 7, n=7.
The zigzag trend that occurs with each successive layer confirms that the layers
are being assembled electrostatically. The ^-potential values for the TGFf3i deposition
steps are indicated in red, for clarification. In each instance, the steps for inclusion of the
growth factor are weakly negative, having a ^-potential value of ~ 15 mV. The layer
steps involving PSS are also negatively charged, but more so than those which
incorporate TGFpY Throughout the LbL assembly, the PDDA deposition steps are very
strongly charged, with ^-potentials between +50 and +60 mV.
Upon initial inspection, the negatively charged values for TGFPi are incongruent
with the fact that its isoelectric point lies at pH 9. One would expect the protein to be
positively charged at pH 7. However, in preparation of the TGFPi, the protein BSA was
incorporated as a carrier molecule. It is likely that incorporation of negatively charged
BSA (MW 66 kDa, isoelectric point pH 4.7) occupies many of the positively charged
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ionizable groups in the protein (MW ~44 kDa), and even overcomes the protein's charge,
due to the larger size. Moreover, several have commented on the capability to easily
incorporate proteins within an LbL film, whether it is anionic or cationic [88, 89, 92].
Evidence supports the fact that proteins do not form their own intact layers but rather are
solubilized by the adjacent layers [91].
5.3.2.2 OCM measurements
The QCM technique was employed to determine the thickness of TGFpV
embedded films, and measurements were performed as previously described. The results
show a linear increase in thickness with each deposited layer pair (Figures 5.10-5.12).
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Figure 5.10. Progressivefilmthickness for TGFPi in the deep loading modality for assembly using (•)
the substrate dipping method and ( • ) nebulization, n=3.
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For

the

scheme

TGFpi-D,

consisting

of

(PDDA/PSS)3/(PDDA/TGFpi)

(PDDA/PSS)3,the nebulization process produces a cumulative thickness of 8.49 nm while
the conventional substrate dipping technique produces a cumulative thickness of 18.95
nm. The peaks shown at deposition step 8 correspond to the incorporation of TGFPi
within the film assembly.
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Figure 5.11. Progressivefilmthickness for TGFPi in the double-layered loading modality for assembly
using (•) the substrate dipping method and (•) nebulization, n=3.
For the scheme in which TGFPi is incorporated after each PDDA layer (TGFPiDL), nebulization yields a cumulative layer thickness of 9.7077 nm. In this instance, the
substrate dipping technique produces a total film thickness of 23.06 nm. Large growth
steps of ~ 6 nm occur when the growth factor is incorporated within the film, as shown
here at deposition steps 8,10,12, and 14.
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Figure 5.12. Progressivefilmthickness for TGFpi in the double-layered loading modality for assembly
using (•) the substrate dipping method and (•) nebulization, n=3.
When TGFPi was incorporated as a terminal film layer (TGFPi-SF), the
cumulative film thickness reached 11.42 nm. Layer 14 is step at which the growth factor
is incorporated into the film. For both the substrates coated with TGFPi-D and TGFPiDL loading modalities, deposition of the protein increases the film thickness and
subsequent adsorption of PDDA leads to a decrease in film thickness. The total growth
step for a bilayer of TGFpi/PDDA fabricated by nebulization is ~1 nm while the substrate
dipping process produces TGFpi/PDDA bilayers which correspond to a growth step of
~4 nm. In each case, it is implied that some of the previously adsorbed protein layer
becomes solubilized upon deposition of PDDA, however, there is enough charge exposed
for electrostatic adsorption of a subsequent layer. The molecular conformation of the
protein within the film structure is non-uniform and complex, as proteins can be larger
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and less flexible than PE chains. This behavior in terms of QCM adsorption kinetics is
commonplace for LbL deposition of proteins while polypeptides and polyelectrolytes are
more uniformly charged allowing for preservation of a continuously increasing film
structure [91].
The fabrication of 14-layered films by spraying process was achieved over a
matter of minutes, a time frame in which only one layer could be deposited using the
substrate dipping method. For instance, a 30 second substrate-PE contact time was
required for deposition of the initial PE layer, followed by a 30 second rinse in DI H2O.
Typically a time of 1-2 minutes was required between PE deposition steps to decant
residual PE solution, rinse out the nebulizer chamber with DI H2O, and add the
subsequent PE solution. Also during this time, additional evaporation and drainage could
occur [151]. Thus, the deposition of one layer using the nebulization technique was
accomplished in 3 minutes, giving a total fabrication time of about 42 minutes for a 14layered film. With the traditional substrate dipping method, only about four layers can
built up within this same timeframe; LbL buildup in this fashion requires minimum
contact times of 10-15 minutes, as well as 3-minute rinses in DI H2O. Therefore, it
would take between 3-4 hours to fabricate a film consisting of 14 layers. Hence, LbL
assembly by nebulization can scale up the fabrication process by at least 6-fold.
Moreover, smaller spraying times of 1-10 seconds have been investigated by others,
offering the possibility for fabrication of multilayer films even more expeditiously [150,
151].
There are still some unknown or uncontrollable parameters within the
nebulization process, such as the power output and the density of droplets through the
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nebulizer and the nebulizer tubing. Mist droplet size, for example, could not be directly
controlled, but is notably an important factor to consider both for the coating process and
the resultant effect on the cellular response. Residual solution in the nebulization
chamber is a potential drawback of using the technique as a method of film-buildup. One
way in which this issue was circumvented was to deposit layers on several substrates
until the flow rate was affected. The maximum volume of the chamber was 5 mL, and it
was discovered that to maintain a constant efflux of solution, a minimum volume of
about 3 mL needed to remain in the chamber. In some cases the solutions could be
reused for deposition of other layers. However, after deposition of Ti02 nanoparticle
layers, for example, the chamber had to be rinsed with copious amounts of isopropanol,
followed by several additional rinses in DI tfeO to prevent contamination of subsequent
solutions.
5.3.2.3 Cell culture
An identical set of TGFPi nebulized substrates were prepared as previously
described for cell culture experimentation. The coated substrates used were cut into 0.25
cm pieces, sonicated in 70% isopropyl alcohol for 15 minutes, and placed into the wells
of a 24-well culture dish. Immediately before cell seeding, the substrates were UVirradiated for 30 minutes and rinsed thrice in Hank's Balanced Salt Solution (HBSS).
Human Dermal Fibroblasts (HDFs) were then seeded onto the substrates at a density of
5000 cells/cm2 and allowed to adhere overnight. Cells were then cultured in 1 mL of
Dulbecco's Modified Eagle's Medium (Cellgro), supplemented with 10% fetal calf serum
(Hyclone), and 1% penicillin/streptomycin (Mediatech). The cultures were maintained in
95% humidified air, 5% C0 2 environment at 37°C.
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To investigate the influence of nebulized films on the growth and function of
HDFs, cells were seeded on uncoated glass substrates and used as a negative control.
Three experimental cell culture groups were established based on layer composition and
architecture. The cells grown on substrates coated with architectures of TGFpi-DL,
TGFPi-SF, and TGFPi-D were cultured in completed DMEM. Furthermore, as a positive
control, cells seeded on uncoated glass were grown in DMEM containing lOng/mL
TGFPi (termed TGFpi-M).

Cell culture medium (with or without growth factor

supplements) was replenished every two days in a volume of 1 mL. Each experimental
group was maintained and analyzed for a period of 21 days.
Cells cultured on the nebulized nanosubstrates were characterized

for

mitochondrial activity, double-stranded DNA, and the presence of the ECM protein, typeI collagen.
5.3.2.3.1 Cell viability
Live/Dead viability of HDFs was analyzed at 4, 7, 14, and 21 days post-seeding.
A Live/Dead working solution (Invitrogen) was prepared by diluting 20 uL of ethidium
homodimer-1 (EthD-1) and 5 uL of calcein acetoxymethyl (Calcein AM) in 10 mL of
HBSS without phenol red. After rinsing substrates thrice in HBSS without phenol red,
samples were incubated in 100 uL of Live/Dead solution for 30 minutes.
Samples were viewed on an Olympus FX51 microscope in brightfield, FITC, and
TRITC modes. Use of the FITC filter (excitation 485 nm) allowed for detection of live
cells, which convert the cell permeant, non-fluorescent calcein AM to the fluorescent
product, calcein. In the TRITC mode (excitation 540 nm), dead cells fluoresce due to
EthD-1 traversing damaged membranes.

Images were acquired with a monochrome
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camera (type) and saved as tag image file format (TIFF) files. 8-bit grayscale images
were colorized and merged to show dualfluorescenceusing Adobe Photoshop. Figure
5.13 shows the Live/Dead images for HDFs at 14 days post-treatment for each of the
experimental groups.

Figure 5.13. Live/Dead for TGF0, (A) control, (B) TGFPi in media, (C) TGFprdeep, (D) TGFpVdouble
layered, (E) TGFpVsuperficial. A and C scale bar=50 ^m, B, D, E scale bar=100 |xm.

The figures here are representative of cytotoxic response to HDF culture in the
presence of TGFpVembedded nebulized films. Overall, it can be seen that there are show
that there are few dead cells (red fluorescence) in comparison to the live cells (green
fluorescence) which are apparent within images of the various experimental groups.
5.3.2.3.2 Mitochondrial activity
Cellular viability was measured through the MTT Assay. MTT is a reduced to a
purple formazan product in mitochondrially active cells (Appendix E). A stock solution
of (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was prepared at
5 mg/mL in PBS. The stock solution was further diluted in completed DMEM in a 1:10
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ratio.

The 10% working solution was freshly prepared before each use. For each

sampling point (4, 7, 14, 21 days) cell culture media was decanted and the glass
substrates for each treatment were rinsed thrice in HBSS without phenol red. A volume
of 100 uL of MTT working solution was added to the samples and the cells were
incubated for a period of 24 hours at 37C. After the incubation time, the purple formazan
precipitate was dissolved with 100 uL of 70% isopropyl alcohol. The solutions were then
transferred to 96-well plates and absorbance was immediately measured at 570 nm using
a reference wavelength of 690 nm (Tecan Sunrise Spectrophotometer). An average of
three measurements for each sample was obtained. The results appear in Figure 5.14.
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Figure 5.14. MTT results for TGFB,-embeddedfilmsproduced by nebulization in deep (D), double-layer
(DL), and superficial (SF) configurations. Results are compared with positive and negative controls and
normalized to Day 4 controls, error bars equal 1 SD, n=3.
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The maximum metabolic activity measured over each experimental group
occurred at 7 days for the TGFPi-D, and 14 days for both the D and DL preparations. For
each measured time period, the positive control with the growth factor incorporated in the
cell culture medium (termed TGFPi-M) resulted in the smallest metabolic activity levels.
This could be an indication that the cells are not receiving as much of a stimulus as that
which is provided by other loading modalities. At day 14, the cells grown on TGFpi-DL
slides are more metabolically active than the controls, suggesting that some
overproliferation was induced. Indeed, it is known that a very small amount of the
growth factor was available for cellular action when simply added to the media.
Conversely, in the DL loading preparation, it is conceivable that the highest amount of
TGFPi was available to induce cellular response. The SF preparation most likely showed
some high metabolic activity initially, however, there is no data presented here for Day 1,
which would support this claim. It is possible that for cells cultured on substrates with
TGFpi in the D configuration, a significant effect on mitochondrial activity would be
seen later than 21 days, due to the position of the growth factor.
5.3.2.3.3 DNA quantification
The amount of double-stranded DNA was quantified to investigate the influence
of TGFpi loading modality (M, D, DL, SF) on cellular function.

For each sampling

period (1, 4, 7, 14, 21 days), cell lysate was recovered and stored at -80°C until needed
for analysis. For a detailed protocol, see Appendix F. Quant-iT™ PicoGreen® dsDNA
reagent (Invitrogen) was used to quantify the amount of DNA present in the samples' cell
lysate. The PicoGreen reagent was diluted 1:200 in IX TE buffer and protected from
light. In a black 96-well plate, 10 uL of cell lysate was diluted in 90 uL TE buffer. The
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PicoGreen working solution was then added to each sample in a volume of 100 uL. The
plates were incubated for 5 minutes in the dark. An excitation wavelength of 485 nm was
used, and fluorescence intensity was read at an emission wavelength of 538 nm (Tecan
Genios Platereader). Results obtained from these measurements over the 21-day period
are shown in Figure 5.15.
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Figure 5.15. DNA quantification for cell culture on TGFPi nebulized substrates. Fluorescence intensity at
538 nm is background corrected to TE buffer, n=3.

The HDFs which received no TGF|3i supplementation showed a steady increase in
DNA content over the testing period. The positive control group, termed TGFpi had the
highest DNA content at 4 days post-treatment.

The DNA content for this group

decreased until 14 days post-treatment, after which time it remained nearly stable. For
cells cultured on TGFpyioaded films, the DNA content fluctuated between 3200 and
3700 pg/mL throughout the experimental period.
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5.3.2.3.4 Cell morphology and
localization of BrdU
and collagen I
To determine the degree to which mitotically active cells expressed proteins
representative of a fibroblast phenotype, 5-Bromo-2'-Deoxyuridine

(BrdU) and

endogenous type-I collagen were co-localized in cells cultured on control and
experimental substrates at 1, 4, 7, 14, and 21 days. BrdU is a mutagen that replaces
thymine in DNA during cellular replication. A 5 mg/mL stock solution of BrdU (Sigma)
was prepared in HBSS without phenol red and syringe-filtered. A working solution of
BrdU in completed DMEM in a 1:100 dilution was prepared fresh for each use. On the
sample day, existing media was decanted from substrates, and replaced with 1 mL of
BrdU/DMEM. The samples were incubated for 24 hours at 37°C.

Following the

incubation period, substrates were rinsed in HBSS and cells were fixed in 95% ethanol at
room temperature for 20 minutes. Cell substrates were preserved in PBS until further
use. A double immunofluroescence labeling technique was used for visualization of
collagen-I and BrdU immunoreactivity within the same sample (Appendix G).
Figure 5.16 shows the differences in HDF morphology for each experimental
group, using differential interference microscopy. The images were acquired using a 40X
objective.
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Figure 5.16. DIC images of fixed HDFs cultured on substrates with loading modalities (A) control and (B)
culture with TGFPi supplemented in the cell culture media. (C) TGFpVdeep, (D) TGFpVdouble layer and
(E) TGFpVsuperficial. The scale bar represents 25 um.

From Figure 5.16, it can be observed that at 14 days, the cells cultured in the
presence of TGFpVsupplemented media have larger nuclei and cell bodies than any of
the other experimental groups. In Figure 5.16 A, and to a larger extent in Figure 5.16 D
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and F, the HDFs have very distinct cellular processes that appear to be anchoring them to
the substrates. Interestingly, each of these substrate preparations consists of a terminal
layer of TGFPi with BSA as a carrier molecule.
BrdU analysis of HDFs cultured under each of the experimental conditions is
shown in Figure 5.17. A positive reaction, indicated by the high intensity red staining,
was obtained in all cases.

Figure 5.17. BrdU localization for HDFs cultured on substrates with loading modalities (A) control and
(B) culture with TGF0! supplemented in the cell culture media. (C) TGFpVdeep, (D) TGFprdouble layer
and (E) TGFprsuperficial. The scale bar represents 25 urn.

Again, it can be noted that the cells cultured in TGF|3i-supplemented media are
larger and have a different morphology when compared with those from any of the other
preparations. These cells (Figure 5.18 B) are wider, larger, and not spindle-shaped as is
the case for the other growth conditions. A representative image of collagen I
immunocytochemical detection is presented in Figure 5.18.
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Figure 5.18, Fluorescent image of collagen I immunoreactivity in HDFs cultured on TGFpVSF substrates
at 21 days post-treatment. The scale bar represents 25 urn.

There is very intense immunoreactivity for collagen I in this instance, as there is a
great deal of contrast between the background and the regions of interest. However,
other samples, such as those for cells cultured on TGFPi-D substrates, appeared to show
no immunoreactivity at first glance. It was later determined that a fluorescence signal
was present; however, it could not be obtained under the default exposure-time setting.
In attempts to connect a quantitative value with the collagen I signal, the minimum
exposure required to obtain a fluorescence signal was recorded for the 21 days posttreatment samples. In this way, it is assumed that the background fluorescence across all
preparations was the same. The minimum exposure times for signal acquisition at 40X
magnification for each of the preparations is provided in Table 5.7.
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Table 5.7 Minimum Exposure Times for Collagen I Fluorescence Signal Acquisition
EXPERIMENTAL
GROUP
Day 21

MINIMUM
EXPOSURE TIME (ms)
Collagen I signal

Control (no additive)
TGFp r M
TGFp,-D
TGFPrDL
TGFp r SF

FLUORESCENCE
INTENSITY

9.1
66.1
14.6
3.6
11.7

6902.249
3110.734
5492.821
7553.568
6269.819

Comparison of the minimum exposure times and intensities for fluorescence in
each

experimental

group

allows

for

a

relative

comparison

on

collagen

I

immunoreactivity, where the largest fluorescence signal corresponds with the smallest
exposure time.

The group with the smallest minimum exposure time and largest

fluorescence intensity, was the TGFpVDL group, indicating that cells in this group were
producing the largest immunoreactivity to collagen I. Likewise, the group with the
highest minimum exposure time (66.1 ms) was the TGFpVM group, having the weakest
immunoreactivity to collagen I. The exposure times for acquisition of BrdU at 40X
magnification ranged between 1000 and 2500 ms, indicating that these signals were much
weaker and more difficult to detect than those of collagen I.

5.4 Conclusions
LbL film fabrication was successfully elaborated over planar glass substrates
using an ultrasonic nebulizer.

Aside from traditionally used PEs, colloidal Ti02

nanoparticles, the drug DEX and the growth-factor TGFPi were easily incorporated
within the film structure during this process. Much of the work presented here was an
initial attempt to characterize the nebulized films, in terms of interfacial chemistry, as this
has yet to be reported. Furthermore, preliminary in vitro testing of the growth factor-
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loaded substrates was performed using human dermal fibroblasts (HDFs). Specifically,
the effect of TGFPi nebulized coatings were evaluated in terms of adhesion, DNA
content, mitochondrial activity, and collagen I production of HDFs over a three-week
period. Cellular processes indicative of greater substrate adhesion were noted on TGFPi
functionalized substrates which incorporated the protein in a superficial layer, when
compared with both HDFs cultured on glass slides and HDFs cultured on glass slides in
media supplemented with TGFpi. Assessment of mitochondrial activity indicated a
maximum proliferation at 7 days for TGFPi in the D configuration, and at 14 days for the
DL and SF loading schemes. Each loading scheme resulted in a higher DNA content
compared with the control over 7 days. HDFs cultured on substrates with TGFPi in the D
configuration demonstrated the highest DNA content over the 21-day period.
Incorporation of TGFPi in the DL configuration led to the highest collagen I
immunoreactivity after 21 days of treatment. These results were not correlated to a
specific release of TGFPi over time, which surely has an effect on the cell response. In
theory, the amount of TGFPi incorporated into the multilayer architectures is on the order
of mg/cm /day, when compared with only a few ng/cm /day for the positive control.
Release studies should be conducted to determine the dissolution of TGFPi from the
multilayered assemblies to further support the data obtained from cell culture
characterization.
HDFs culture on substrates containing TGFPi in a superficial position
demonstrated heightened mitochondrial activity and the presence of distinct cellular
processes at 14 days, which could be indicative of enhanced cell adhesion.
Furthermore, differences in loading modalities of the growth factor may lead to
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alterations in cellular differentiation processes, as evidenced by assessment of collagen I
immunoreactivity.

The ability to influence cell phenotype is certainly a promising

outcome of this technology. A more detailed analysis of cell-substrate interactions is
warranted, as there are still many unknowns, such as how the deposition times, distances,
and film composition affect film composition, rigidity, and cellular responses with varied
cell types. The results strongly indicate that the nebulization technique produces quality,
organized film architectures while having an addition benefit of expediting film
fabrication. Certainly, these two properties can be extremely advantageous in the coating
of implants or other biomaterials, but the cost fabricating growth factor and drug
embedded films must be considered in the context of scale-up.

Nonetheless, it is

envisioned that the inclusion of this and other growth factors or other bioactive agents
could be used for enhancement of dental and orthopedic implants, or in the form of a
bioactive bandage for support and enhancement of the initial stages of cutaneous wound
healing.

CHAPTER 6
CELLULAR ENCAPSULATION WITHIN NANOTHIN
CAPSULES USING LAYER-BY-LAYER ASSEMBLY
6.1 Introduction
Cellular encapsulation within polymer complexes has recently been an intense
area of study, particularly as method for creation of an artificial pancreas in which Islet of
Langerhans cells can be encapsulated in an alginate hydrogel [154, 155]. Within the
encapsulation matrix, these cells are still capable of retaining their function, producing
and exporting insulin. Awareness of the ability to retain islet function within permeable
shells and matrices has prompted others to investigate the encapsulation of other cell
types, including fibroblasts, chondrocytes, hepatocytes, and mesenchymal stem cells
(MSCs) [52,156-159].
Precise control of the microenvironment provides a means through which MSCs
can give rise to a number of cell types, including chondrocytes, adipocytes, osteoblasts,
neurons, and others [40]. It is their vast differentiation capability coupled with an innate
self-renewal property that offers the possibility for treatment of numerous disease states
and clinical issues. Whether the cells achieve and maintain a desired phenotype depends
upon on a diverse set of extracellular environmental cues designed to direct and regulate
cell behavior. The bone morphogenic proteins (BMPs) and members of the
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transforming growth factor (TGF) superfamily are among the most studied signaling
molecules, which have been identified as playing an important role in initiating pathways
that lead to the differentiation and preservation of various cell types [123].
MSC differentiation in situ, however, poses a great challenge. Many substances
used to enhance cellular function in vitro are not necessarily successful in vivo. For
instance, monolayer culture of MSCs in the presence of osteogenic supplements such as
dexamethasone, ascorbic acid-2 phosphate, and p-glycerol phosphate results in osteoblast
lineage commitment and matrix mineralization, but has been shown to suppress in vivo
bone growth in certain instances [159]. Therefore, in an in vitro setting, the simple
addition of these molecules while providing instructional cues into the cellular
environment, is unregulated, and has been shown to be insufficient in producing the
desired extracellular matrix (ECM) architecture required in tissue-engineered implants
due to their short half lives [160-162]. A means to regulate delivery of a suite of signaling
molecules, ideally in a multi-stage framework of release, both spatially and temporally, is
highly desired. Thus, it follows that bioencapsulation as first suggested by Chang in
1964, is a promising method to orchestrate the appropriate interaction between cells,
instructional molecules, and the microenvironment leading to desired tissue-engineered
constructs [163]. Futhermore, encapsulation of MSCs allows for creation of an in vitro 3D microenvironment, and for the concerting of soluble signals both temporally and
spatially, thereby better approximating MSC behavior to that witnessed in a native
milieu.
The overarching goal of this project was to individually encapsulate cells within
nanothin layers consisting of biocompatible polyelectrolytes and growth factors.

To
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accomplish this goal the layer-by-layer assembly (LbL) technique was chosen because of
the mild assembly conditions, nanoscale precision, tuneability, and the potential for
surface modification. Through this process, the negatively charged cell membrane can be
encased within a cationic polymeric shell; oppositely charged polymers can be
subsequently adsorbed to achieve a desired thickness and surface composition. The
polyelectrolyte multilayers can be tuned to generate thicknesses from 5 to 50 nm, and
alter capsule permeability based on composition and layer number [73, 152, 164]. It has
been shown that poly(styrene sulfonate) (PSS)/ poly(allyamine) (PAH) layers on
echinocytes were useful in generating nanotemplated cell capsules [78]. Moreover, a
study by Diaspro et al. reported that prokaryotic cells encased within PSS/PAH
polyelectrolyte shells were able to maintain their viability, functionality, and normal
exchange of nutrients and waste [165]. LbL assembly has been used to modify platelet
surfaces with antibodies as a means of investigating targeted delivery mechanisms within
the walls of blood vessel substitutes [166] and for encapsulation of E.coli cells [167].
Alternatively, appropriate selection of polymers can also be exploited for the fabrication
of stealth cellular vehicles. The masking of cells in this fashion could make them
immunologically invisible, a desirable property in the case of allogenic transplants.
In this study we demonstrate the ability to individually encapsulate mouse
mesenchymal stem cells (MSCs) and human dermal fibroblasts (HDFs) within
multicomponent shells consisting of various materials suitable for LbL assembly,
including

polyelectrolytes, drugs, and proteins. The sections that follow include

materials characterization and acute cell viability studies for MSCs and HDFs
encapsulated within different capsular matrices.
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6.2 Materials and Methods
6.2.1

Preparation of Polyeleetrolyte,
Nanoparticle, Protein, and
Drug Solutions
Materials suitable for LbL assembly were used, including synthetic and natural

PEs, charged colloidal nanoparticles, and water-soluble protein growth factors. The PEs
hyaluronic acid (HA), poly(L-lysine), (PLL, MW 30,000), poly (styrene sulfonate)
sodium salt, 30% (PSS), poly(dimeththyldially ammonium chloride), 20% (PDDA, MW
400,000), chondroitin-6 sulfate (CS, MW 60,000), poly(L-aspartic acid sodium salt, MW
15,000 - 50,000) (PLAA protamine sulfate (PS, MW 70,000) were obtained from Sigma
Aldrich. All PEs were prepared between 1-3 mg/mL in DI H 2 0, HBSS, or 0.5 M NaCl
when indicated. Titanium Dioxide (P25 Degussa AG, Germany) diameter ~21 nm, was
prepared in DI H2O at a concentration of 6 mg/mL and adjusted to pH 4 with dilute HC1.
Growth factors were prepared according to the supplier's recommendations.

Briefly,

rHBMP2 (ProSpec, Israel) was reconstituted in 20 mM of sterile glacial acetic acid, and
further diluted in Phosphate Buffered Saline (PBS) to give a stock concentration of 100
ug/mL. 1 ug of TGFPi (ProSpec, Israel) was reconstituted in 4 mM HC1 containing 1
mg/mL of Bovine Serum Albumin (Sigma) to yield a stock solution of 1 ug/mL. The
growth factor stock solutions were then diluted with either cell culture medium or buffer,
as appropriate for experimental use, to give a final concentration of lOng/mL. Table 6.1
details the molecules used and their associated isoelectric points.
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Table 6.1 Isoelectric Points of Poly electrolytes, Nanoparticles, and Biomolecules
MOLECULE

ABBREVIATION

PI

Bone Morphogenic Protein-2
Chondroitin Sulfate
Hyaluronic Acid
Poly(L-aspartic acid)
Poly(styrene sulfonate)
Poly(dimeththyldially ammonium chloride)
Poly(L-lysine)
Protamine Sulfate
Titanium Dioxide
Transforming Growth Factor Beta-1

BMP2
CS
HA
PLAA
PSS
PDDA
PLL
PS
Ti0 2
TGFpj

9
3.2
2
2.8
2
12
9
10-12
5
8.9

6.2.2 Fabrication of Cellular
Capsules
Mouse MSCs (ATCC-CRL 12424) were cultured in completed Alpha-Modified
Eagle's Medium (10% fetal bovine serum, 1% penicillin/streptomycin, 2mM
L-glutamine). HDFs were cultured in Dulbecco's Modified Eagle's Medium (Cellgro),
supplemented with 10% fetal calf serum (Hyclone), and 1% penicillin/streptomycin
(Mediatech). Cells were incubated at 37 °C in a 5% CO2, 95% humidified air
environment.
A cationic solution was added to the cell suspension for deposition of the first
layer. After layer adsorption had been achieved, three intermediate washings with HBSS
were made at 37 C using centrifugation at 1000 rpm for 5 minutes. Subsequently, the
counterionic layer was adsorbed in the same manner. This process was repeated until the
desired layering scheme was achieved. Figure 6.1 provides an illustration of thin film
deposition onto a cellular template using the LbL technique.
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Figure 6.1. Illustration of cell encapsulation process, in which the negatively charged cell can be coated
with polyelectrolytes (gray and red lines), as well as nanoparticles, or biologically relevant molecules
(small circles)

6.3 Results and Discussion
6.3.1 MSC Encapsulation in Biocompatible Shells
Bilayers of PLL/HA or PLL/BMP2 were deposited onto MSC templates as
described in Section 6,2.2,, so that a layering scheme of MSC/(cationic solution/anionic
solution)n was attained, where n=l-3. PLL and HA were used at 1 mg/mL. A deposition
time of ten minutes was typically used for PEs and BMP2 was allowed to adsorb for 30
minutes, PLL and HA solutions (1 mg/mL) were prepared in each of the following
solvents; DIH20, Hank's Balanced Salt Solution (HBSS), and 0,5 M NaCl, Cationic PLL
was first added to a 5xl06 cells/mL suspension of mouse MSCs, After the washings in
HBSS, the anionic HA or 10 ng/mL BMP2 was adsorbed.

In the instance where

PLL/BMP2 films were formed on the MSCs, PLL was added to a cell suspension of
2xl06cells/mL,
6.3.1.1 Zeta-potential measurements
Layer adsorption for each step was monitored by electrokinetic ^-potential
measurements. For the purpose of these measurements, washings were carried out in DI
H2O. Washing in this manner, as opposed to HBSS, was necessary to verify alterations
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in surface charge with the addition of each polyelectrolyte layer. Figure 6.2 presents the
net surface characteristics for MSCs encapsulated in two bilayers of PLL/BMP2 and
PLL/HA.

- PLL/HA
- PLL/BMP2

Layer

Figure 6.2. Surface charge inversions for encapsulated MSCs in PLL/HA and BMP2/HA bilayers

The addition of polymer and protein growth factors layers to the cell suspension
results in alternation of surface charge with each deposition step. As shown in Figure 6.2,
the ^-potential of bare MSCs is negative; however, the MSCs coated with PLL/BMP2
carry a much smaller £- potential (~ -20 mV) than those coated with PLL/HA layers (~ 50 mV). The PLL adsorption steps are also notably fewer for the BMP2 preparation
when compared with the HA preparation. In theory, one would expect similar surface
charge measurements for deposition of PLL layers onto the cell templates. Two factors
are in play here. One major influence is that there is a difference in electrostatic
interactions between the layer ionizable groups. Secondly, the difference in the initial
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concentration of cells used in the fabrication process may have affected these interactions
based on ionizable groups or overall charge density which could determine the quality of
subsequently deposited layers. Moreover, because proteins have the capacity to behave
as dipoles, variations in the charge magnitudes could be attributed to various matrix
proteins within the immediate environment, either synthesized by the stem cells and
deposited in the pericellular matrix, or donated from the serum in the culture media [19,
95,168].
When the terminating layer is PLL, the cell surface is positive. Similarly, with
each HA or BMP2 deposition step, the outermost layer of the cell is rendered negative.
When PLL is a terminal layer, the cell surface is positive. Similarly, with each HA or
BMP2 deposition step, the outermost layer of the cell is rendered negative. One will
notice that the PLL deposition steps which are alternated with HA have a smaller surface
charge than the PLL alternated with BMP2. The differences in magnitude for the PLLdeposition steps when compared with the HA steps are a product of the chemical nature
of each polyelectrolyte, and the pH at which the layers are assembled. HA has an
isoelectric point of approximately 2.9 while both BMP2 and PLL have isoelectric points
of 9 [98]. For the case of the PLL/HA films, both polyions are almost completely
dissociated at neutral pH, but PLL is more dissociated than HA, because the isoelectric
point of PLL is further from the assembly pH than that of HA. According to Burke and
Barrett, under these assembly conditions HA is more weakly charged and assumes a
loopy conformation while PLL assumes a more rigid conformation [169]. In addition, HA
is much larger than PLL, and thus carries a higher charge density.
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For the case of the PLL/BMP2 films the same behavior was expected. It is,
however, noted that the behavior of polypeptides and proteins within LbL films is quite
complex due to their non-uniform molecular conformation and surface charge densities
[91]. Nonetheless, enough BMP2 is deposited to allow for both the initial electrostatic
interactions with the underlying layer, as well as surface charge reversal to allow for
deposition of a subsequent layer. From additional ^-potential measurements over time, it
was discovered that in theory, BMP2 could be alternated with either a positive or negative
PE, as the net charge characteristics of the protein are altered with time. The precise
mechanism by which this charge ambiguity occurs is unknown, however, this observation
is in agreement with the work of others, in which BMP2 has been incorporated within
LbL films as both cationic and anionic constituents [88, 89, 92].
6.3.1.2 QCM measurements
QCM analysis was completed at each growth step to monitor the layer deposition
and determine the shell thicknesses produced. The results are shown in Figure 6.3. The
PLL/HA bilayer thickness is approximately 1 nm, producing a two-bilayer shell of 2 nm
thickness in the dry state. For a two-bilayer shell composed of PLL/BMP2, the thickness
is around 4.5 nm. (Figure 6.3). In the hydrated state, the LbL multilayer thickness is
approximately twice as large, with an estimated shell thickness of 6 and 9 nm, for layers
with HA and BMP2, respectively [73,108].
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Figure 6.3. QCM for deposition two bilayers (PLL/HA) and (PLL/BMP2)

The peaks which appear in the figure correspond to the adsorption steps for
BMP2. It is noted that adsorption of PLL onto the BMPa layer causes an increase in
resonator frequency, which correlated to a decrease in thickness by roughly 1 nm. With
the next BMP2 deposition step, the thickness increases again by around 2.5 nm. Based on
the observations here, it is hypothesized that upon immersion of the coated cells in
culture media, portions of the BMP2 layer are immediately solubilized, decreasing the
total shell thickness.
6.3.1.3 Fluorescence microscopy
To visually confirm the presence of polyelectrolyte layers on the MSC templates
and to assess biocompatibility, the encapsulation process was repeated using fluorescein
isothiocyanate (FITC) tagged PLL. The FITC molecule covalently binds to exposed
amine residues, causing the PLL molecule to fluoresce at 530 nm when excited with 488
nm laser light. Figure 6.4 shows the results.
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Figure 6.4. Confocal Micrograph for MSC/PLL/HA. Confocal micrographs of MSCs encapsulated
within PLL-FITC/HA at (A) three days post-encapsulation and (B) seven days post-encapsulation. Insets
show phase micrograph for reference, (Leica Laser Scanning Confocal Microscope, SP2).
The confocal image at three days post-encapsulation clearly shows the adsorption
of PLL onto the cell membrane, forming an exact template (Figure 4A). The confocal
micrograph at seven days post-encapsulation (Figure 4B), however, does not show the
presence of a discrete red fluorescent layer and demonstrates a greater amount of
fluorescence within the cell when compared with the three-day image. The presence of
PLL-FITC within the immediate pericellular matrix is attributed to the ability of free PLL
to diffuse in and out of the PLL/HA film, coupled with endocytosis of the polyelectrolyte
[88,89,98,170,171].
In vitro cell viability studies were conducted using MSCs encapsulated within
three bilayers of PLL/HA. Polyelectrolyte solutions were prepared in DI H2O, HBSS, or
0.5 M NaCl and adsorbed onto the cell as described earlier. For each preparation, cells
were seeded at a density of 5000 cells/cm2 and viability was assessed using the
Live/Dead Assay (Biovision). Images were acquired with a Nikon microscope coupled to
a Nikon E995 digital camera. In terms of viability, similar results were observed over the
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seven-day period for all solvents (Figure 6.5). For cells to remain viable in culture,
proper pH, osmotic and ionic balance are crucial.

This notion brings about the

conclusion that although the cell are exposed to PEs dissolved in unbalanced solvents for
several minutes, they are either not greatly affected or have the ability to recover from a
negative outcome. After each deposition step of shell buildup, the cells undergo three
washings in HBSS. This medium contains various salts which support cellular function
and nutrient transport. Undoubtedly, these washings play a role in the maintenance of
membrane integrity and cellular viability.
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Figure 6.5. Live/Dead images of MSCs encapsulated within three bilayers of PLL/HA. Polyelectrolytes
were suspended in deionized water (A-12 hrs post-encapsulation and B-7 days post-encapsulation), 0.5 M
NaCl solution (C and D, 12 hrs and 7 days post-encapsulation), and HBSS (E and F, 12 hrs and 7 days
post-encapsulation). The scale bars on each image represent 50 urn.

Similar morphological results to those seen in Figure 6.5 were obtained when the
encapsulated cells were observing with bright field microscopy. Cell clusters and
aggregates form (Figure 6.6) after 6 days.
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Figure 6.6. Brightfieldimage of MSCs within PLL/HA shells at 6 days post-encapsulation.
Polyelectrolytes were dissolved in HBSS. The image was acquired with Nikon system. Original
magnification, 100X.

6.3.1.4 Mitochondrial activity
The MTT Assay (Invitrogen) was performed at one, three, and seven days postencapsulation. MSCs coated with two bilayers of PLL/HA were seeded at a density of
10, 000 cells per well in a 96-well plate and incubated in a growth medium for the
designated time period. The cells were incubated in MTT solution overnight.

The

formazan precipitate was dissolved with 100 mL of MTT solvent (Sigma) and absorbance
was immediately measured at 570 nm using a reference wavelength of 690 nm (Tecan
spectrophotometer). The results of the MTT Assay for PEs dissolved in HBSS is
provided in Figure 6.7.
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Figure 6.7. MTT Assay for MSCs encapsulated within two bilayers of PLL/HA. Control cells were
grown without deposition of multilayer shells. Polyelectrolytes were suspended in HBSS and then adsorbed
onto MSCs as described above. A student's t-test with p«=0.05 was used to determine statistical
significance (denoted by the asterisks).

The uncoated cells showed a steady increase in metabolic activity between one
and seven days of maintenance. Conversely, the metabolic activity of the encapsulated
cells steadily declined over the seven-day culture period. As shown in Figure 6,7, a
significant decrease in mitochondrial activity, and thus cell proliferation, was noted
between one and three, and one and seven days post-encapsulation.

There is no

significant decrease between metabolic activity between the two groups at 1 day postencapsulation, but as the encapsulation time is extended, the difference between the
controls and encapsulated cell metabolic activity becomes increasingly great.

The

argument can be made that since the cells are not in their native environment, i.e.
anchored to a substrate, the results seen here could simply indicate that they are not as
mitochondrially active, but still viable.
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Initially, cell viability could not be confirmed through Trypan Blue and MTT
staining. It was assumed that the polyelectrolyte layers were permeable only to smallmolecular-weight molecules. However, this hypothesis was nullified upon inspection of
the molecular weights of the molecules used. Trypan Blue and MTT have molecular
weights of 892 and 414, respectively. The Live/Dead Assay uses molecules which
permeate the cell and form the fluorescent compounds calcein AM (MW 995) and
ethidium homodimer-1 (MW 1293). It has been shown that polyelectrolyte multilayers
are permeable to molecules with a Mw less than 3000 [73, 108]. Based on size
comparisons, if the latter two can permeate the polyelectrolyte shell, one would expect
that Trypan Blue and MTT would have the same potential. Further optimization of
experimental conditions demonstrated the necessity to incubate cells in the MTT solution
and Trypan Blue for a time period greater that what would conventionally be used. These
results are likely due to the increased diffusion pathlength from addition of the
polyelectrolyte layers. It is possible that we did not find any obstacles with the Live/Dead
Assay simply because of its high sensitivity and fluorescent nature.
HA is a natural, linear polysaccharide comprised of D-glucuronic acid and Nacetyl-D-glucosamine. It is a chief component in connective tissue ECM, and plays a role
in wound healing, among several other biological processes [98, 169, 170]. The natural
cation, PLL, is a linear polypeptide containing an amino group and has been widely used
in biomaterial applications to enhance cell adhesion [95, 169, 170]. Previously,
characterization of PLL/HA multilayer films generated by LbL has been achieved using
atomic force microscopy (AFM), {"-potential measurements, quartz crystal microbalance
(QCM) monitoring, and contact-angle measurements [98, 169, 170]. Thus, the promise

127
of using these and other biologically friendly molecules with ionizable groups was further
investigated in this work.
6.3.2

HDF Encapsulation in
TGFBi Functionalized
Shells
Using human dermal fibroblasts as anionic templates, the protein growth factor

TGFPiwas incorporated into the layer coatings. For this purpose, three layering schemes
were considered: deep (D), double-layered (DL), and superficial (SF). Table 6.2
elaborates the film architectures consisting of seven layers, which were built-up onto the
HDFs.
Table 6.2 PLL/TGFpi Layer Architectures
SCHEME

ARCHITECTURE

D
DL
SF

(PLL/TGFP0/(PLL/HA)2-PLL
(PLL/TGFPJ)3-PLL

(PLL/HAMPLL/TGFpO-PLL

6.3.2.1 Zeta-potential
measurements
For the purpose of these measurements, intermediate washings were carried out in
DI H2O. 1.5 mL of PE was added to a 3x109 cells, giving an initial concentration of 0.5
million cells/mL. A deposition time of 20 minutes was used for incorporation of TGF|3i
within the cellular capsule.

The results are provided in Figure 6.8. The HDF cell

template carries a moderate negative charge of around -33 mV. Deposition of the PLL
layer reverses the surface charge so that it carries a ^-potential of approximately +20
mV. With each additional deposition step, the surface charge reverses, demonstration
that the layers are being assembled electrostatically. It is noted that the ^-potential values
obtained for TGFPi layers are weaker than those of HA. However, in comparison to the
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results for PLL/HA and PLL/BMP2 layers on MSCs presented in Section 6.3.1.1, the C,potential measurements for all deposition steps are moderately to strongly charged,
meaning that the initial cell concentration in plays a critical role in establishing strongly
charged layer interactions.

Deposited Layer
Figure 6.8. Adsorption kinetics as monitored by zeta-potential for growth factor incorporation in films (D,
DL, SF). Initial amount of cells used was 4.5 x 106.

6.3.2.2 OCM Measurements
The QCM technique was employed to determine the thickness of TGFPiembedded cellular coatings, and measurements were obtained as previously described in
Section 5.3.2.1. As depicted in Figure 6.9, the growth step of a PLL/TGFPi bilayer
corresponds to a thickness of approximately 3 nm. For a complete shell with TGFPi
incorporated in one of the layering modalities, the total cell coating is only about 12 nm.
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Again, it is expected that in aqueous solution, the LbL assembled layer thicknesses are
doubled, thus a coating with embedded TGFpi has a total shell thickness of around 24
nm.

1
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10
11 12 13
Deposited Layer
Figure 6.9. QCM for encapsulated HDFs comparing TGFJJj in the D, DL, SF modalities

The largest growth steps occur with deposition of TGFPi layers, however, after
deposition of TGFPi the resonator frequency increases, suggesting that mass is being lost.
The underlying principle regarding the observed QCM results is simply that the TGFPi
layers are being solubilized upon deposition of a PLL layer.
6.3.2.3 Viability of encapsulated HDFs
As a final extension of this work, several various bilayer combinations were
deposited onto HDF templates. 25,000 cells were used in each instance for buildup of
thin film capsules. Those PE pairs included (PDDA/PSS), (PLL/HA), (TGFpi/HA),
(PS/CS), (PS/PLAA), (TGFPi/Ti02), (GelA/GelB), and (GelB/CS). The MTT Assay
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was used as a means of comparing cellular response at 3 days post-encapsulation for each
of the preparations. Table 6.3 provides initial ^-potential measurements.
Table 6.3 Surface Charge Inversions for Encapsulated HDFs Comparing Different
Layering Schemes, n=7.
SCHEME
1

Cell Template
-12.47

Layer 1
PDDA
17.86

Layer 2
PSS
-21.18

Layer 3
PDDA
13.27

Layer 4
PSS
-24.33

-15.18

PLL
11.63

HA
-14.35

PLL
14.16

HA
-17.12

-13.74

TGFpj
-4.18

HA
-17.36

TGFp,
-8.42

HA
-21.15

-17.12

PS
7.13

CS
-21.49

PS
13.04

CS
-16.27

-16.23

PS
9.44

PLAA
-14.21

PS
13.41

PLAA
-19.93

-15.21

Ti0 2
8.18

PLAA
-6.14

Ti0 2
12.29

PLAA
-7.13

2

3

4

5

6

In each case, the magnitude of charge at the cell template is around -15 mV.
Proper surface charge alteration was seen in most instances, as the numbers change sign
with each subsequent layer. In scheme 3, the net charge of TGFPi i s -4.18 with its first
deposition step, followed by a negative charge of-17.36 for the HA deposition step. The
fact that the magnitude of charge is small but does not cross zero could be an indication
that there are not a sufficient number of charged sites at which HA can adsorb, neutralize,
and then reverse the sign. The three-day cellular response to encapsulation within shells
of various constituents is presented here in Figure 6.10.
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Figure 6.10. MTT results for various shell constituents. Control cells were grown without deposition of
multilayer shells. Polyelectrolytes were suspended in HBSS and then adsorbed onto MSCs as described
above. A student's t-test with p=0.05 was used to determine statistical significance, n=3.
The control group received no supplementation or additional modifications.
During this time-frame, the HDFs encapsulated within shells of TGFpi and HA had the
highest relative metabolic activity. HDFs encased in shells of the synthetic PEs PDDA
and PSS showed the smallest metabolic activity after three days of encapsulation.
Schemes 1 and 3 showed metabolic activity that was statistically significant from the
controls, when a two-tailed student's t-test was employed.

6.4 Conclusions
The largely preliminary work presented here describes the ability to buildup thin
films on individual mammalian cells. Investigations into film growth, such as the case
for the layer combination PLL/HA have established that the self-assembly process of
natural PEs is comparable to that of synthetic polyeleetrolyte multilayer films, whereby
the surface charge is overcompensated after each polyion deposition step. Moreover,

132
bioactive molecules can be embedded within the film architecture via covalent or
electrostatic interactions without loss of their functional integrity [170]. The inherent
biocompatibility of PLL and HA make their combination highly desirable in tissue
engineering, pharmaceutics, and other biological applications [98,169].
There are several key areas that must be investigated to further this technology for
inclusion in bioactive implant systems. For example, MSC encapsulation in layers of
PLL/HA, was met with a significant decrease in cell viability between one and three, and
one and seven days post-encapsulation. One possibility is that the addition of
polyelectrolyte layers causes some disruption in membrane integrity. Germain et al.
demonstrated that after deposition of each bilayers, incubation of their cell suspensions
for two hours at 37°C in buffer solution increased cell viability [172]. They further
postulated that weak polyelectrolyte interactions may assist with shell flexibility and
further prolong viability by reducing mechanical tension on the cell surface. This is
supported by AFM studies wherein high ionic strength solutions had more flexible shells
when compared with cells encapsulated in polyelectrolytes of low ionic strength [155].
Certainly, further cell viability tests over the long term coupled with AFM
examinations for information concerning shell stiffness and durability, will provide
additional insights into how this technology can be translated into the clinical realm.
While our preliminary results are promising, examination of shell permeability is critical
in assessing the longevity of encapsulated cells.
The ability to include growth factors, biomolecules, and therapeutics within the
cell capsules will further contribute to the development of a comprehensive tissueengineered product.

Therefore, determination of the requisite positioning and
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combination of factors needed to induce differentiation into specific cell types must be
addressed. Fluorescent immunochemistry, SDS page, and ELISA may prove to be
especially useful in accomplishing this task.

Complementary studies in adsorption

kinetics for the embedded proteins, growth factors, or drugs must also be performed, to
determine optimal deposition times. Finally, the precise encapsulation efficiencies for
various coating preparations was not determined, but would prove useful in conjunction
with long term biocompatibility studies as far as scale-up and cost-efficiency are
concerned.

CHAPTER 7
CONCLUSIONS AND FUTURE WORK
7.1 Conclusions
There are trends towards production of multifunctional biomedical devices which
can incorporate varying chemical, mechanical, and biological

characteristics

simultaneously and synergistically. The presented study described the fabrication,
characterization and testing of novel LbL assemblies for incorporation into tissue
engineering systems. The simplicity, versatility, and power of LbL to influence cellular
behavior represents a major inroad in terms of using novel, nanoengineered approaches
for construction of complex, yet functional assemblies which can be exploited for the
improvement of clinical problems. First, the expedited or slowed release of
dexamethasone (DEX) through with DEX aggregates (directly template drug crystals) or
DLCAMs (drug physically immobilized in alginate microspheres) was achieved. The
presence of DEX aggregates in culture medium directed bovine TMJ fibrochondrocytes
toward the chondrocyte phenotype when compared with positive and negative controls.
In another section, ultrasonic nebulization was used to expedite LbL coatings on planar
substrates.

The formation of multi-architecture films with embedded DEX, TiC>2

nanoparticles, and the protein growth factor TGFpi collectively, shows an elegant method
for enhancing for controlling, enhancing, and optimizing cellular response based on
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variations in spray distance, deposition times, and layer composition.

Finally, mouse

mesenchymal stem cells (MSC) and human dermal fibroblasts (HDF) show the ability to
remain viable while individually encapsulated within multilayer shells of varying
compositions. Moreover, incorporation of complex molecular structures, such as TGFpi,
within the shell assembly resulted in heightened cellular mitochondrial activity in
comparison with other shell architectures and unencapsulated cells.

7.2 Future Work
7.2.1

Controlled-Release
Technology
From a clinical perspective, bioavailability of therapeutics in varying quantities

over different time frames is ideal in a tissue-engineered setting. Based on the results of
DEX release from DLCAMs, a sustained release of the drug is theoretically possible for a
period of four months. This behavior is distinctively different from the expedited drug
release from DEX aggregates, and from a practicality standpoint have a much greater
potential for incorporation into a tissue-engineered structure. With that said, however, it
is unknown whether the DEX release from DLCAMs remains pharmacologically and
biologically active over a period of more than a few days. Further optimization studies of
drug release from the calcium alginate matrices should be explored in terms of drug
loading, cross-linking concentrations, sonication power, and mixing speed during the
fabrication process. On a larger scale, the need for a significant amount of testing and
characterization of in vivo cellular behavior correlated to microsphere degradation
behavior, an thin film coatings, as well as analysis of the chemical composition of the
drug over extended time periods is underscored.
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Other possibilities for this technology include multi-stage timed release of various
biologically relevant molecules, for example, multiple growth factors with precisely
controlled-release behavior from a single system.

An interesting approach to this

prospect is successive encapsulations of varying growth factors using calcium alginate
microspheres as spacers.
7.2.2 Nebulized Substrates with
Bioactive Functionality
Variations in the LbL process in concerning surface topography and adsorption
kinetics were noted between the traditional substrate-dipping process and nebulization.
When incorporated in different positions within nebulized film assemblies, HDF response
to TGFPi was modulated over a three-week period, due likelyto temporal and spatial
concentration differences. Investigations into the specific release behavior of TGFPi was
should be pursued to elucidate this and other observations. Also, the noted difference in
size between positive controls (cells grown on glass slides cultured in TGFpV
supplemented media) and the nebulized assemblies is still elusive. Thus, the interactions
between cell behavior, protein adsorption characteristics, and topographical features
should be further explored. In addition, the possibility of architectures consisting of
multiple growth factors and varying concentration gradients could produce interesting
cellular behaviors and varying phenotypes, towards the goal of generating tissues which
closely approximate native cellular organization.
On a larger scale, this technology can be easily modified, for example, as a
method to produce anti-microbial coatings on dental implants, in the fabrication of a
bioactive bandage, which encourages enhanced hemostasis and wound-healing, or for
optical, electronic and other properties towards the design of biosensor platforms and
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arrays. The ability to functionalize the films with specific ligands or antibodies could
also be used as a novel cell-recruitment system.
7.2.3 Cellular Encapsulation
The ultimate purpose of the cell encapsulates is implantation or engraftment into a
tissue defect to assume a particular therapeutic action. Despite the numerous strides in
development of cell encapsulation technologies, implant failure remains a barrier to
clinical implementation. Among the largely unresolved issues is attack by the host
immune system. Within the shell layers, inclusion of anti-inflammatory agents such as
DEX and Ketoprofen could assist in preventing acute inflammatory responses.
The ability to closely mimic natural encapsulation processes, such as that
witnessed during embryonic development of the Drosophila melanogaster [173], could
be a solution to increasing cell viability. Encapsulation also allows insect hosts to
survive infection by parasitoids, and permits bacteria to maintain their virulence via
secretion of a protective polysaccharide matrix [174, 175]. Further investigation into
these natural methods of protective capsule formation may provide a basis for optimal
material selection concerning fabrication of permeable, biocompatible, nanothin layers
onto cells.
Other possibilities of this research branch out into a few directions. For example,
cell populations could be primed within the 3-D capsules and then later dissolve leaving
the cell intact and healthy and available for other uses. Also, there is the potential to
produced organized tissue of varying cellular contents based on self-assembly of cells
with oppositely charged coatings.
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As a final thought, the flexibility and robustness of this technology expresses that
there are endless possibilities for integration of these three technologies to produce novel
composite materials to overcome obstacles in the field of tissue engineering and implant
modification, to better control cellular function and tissue organization.

APPENDIX A
PROTOCOL FOR FABRICATION OF CALCIUM
ALGINATE MICROSPHERES
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Procedure
Briefly, 0.75 g of low viscosity alginic acid sodium salt was slowly dissolved in
24 mL of deionized water while stirring with a propeller style stirrer at a setting of 1.5 for
10 minutes. The desired amount of dexamethasone was added to the mixture and stirred
for an additional 5 minutes. A mixture of 54 mL of isooctane (EMD Chemicals) and
0.848 g Span-85 was ultrasonicated for 1 minute at 39 W. The alginate/drug mixture was
then added to the isooctane/span mixture and sonicated at the same power for 5 minutes.
Further sonication for an additional 2.5 minutes was performed after adding a mixture of
2.95 mL of isooctane and .45 mL of Tween-85. The mixture was then stirred for 20
minutes while slowly adding 10 mL of a 10% calcium chloride solution in deionized
water. The emulsion was diluted with 500 mL of deionized water, added to a separatory
funnel, and collected. Three washings by centrifugation for 3 minutes at 3000 rpm were
performed before use for experiments.

APPENDIX B
FITOCONJUGATION PROTOCOL
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Materials and Equipment Needed
•
•
•
•
•
•
•
•

FITC
PBS
0.5 M Carbonate buffer
10 mL test tubes
Protein or Peptide
DMSO
Vortex
PD-10 column

Procedure
The following protocol can be used to couple FITC to amine residues, as was
done in the case of complexing PLL to FITC.
1.

Dissolve 2mg of protein/peptide in lmL of PBS (pH 8.0) in clean 16x125mm
polypropylene test tube. If needed, adjust pH to 8.0 using 0.5M carbonate buffer.

2.

Prepare fresh, lmg/mL of FITC in DMSO. Add 75uL of FITC/DMSO solution to
protein/peptide while vortexing.

3.

Incubate at room temperature for 45minutes.

4.

Using a PD-10 column, wash PD-10 with 30mL of PBS.

5.

Add the lmL FITC-protein/peptide solution after the top of column is almost dry.

6.

Close stopcock to stop flow after the protein/peptide has eluted into the column.

7

Add 5mL of PBS on top.

8.

Open Stopcock, collect in 2mL fractions, discarding the first 2mL and keeping the
2nd 2mL fraction. The second 2mL fraction contains the conjugated
protein/polypeptide*.
*NOTE: This step is appropriate only if lmL of conjugatedprotein/polyelectrolyte is added to the column. If 2mL of conjugated-Ig is added,
discard first lmL and keep the next 4mL. The antibody is always diluted by 2x
after leaving the column.

APPENDIX C
WST-1 ASSAY
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Materials and Equipment Needed
•
•
•

Flat bottomed 96-well plates
Cell Culture medium
WST-1 Cell Proliferation Reagent

Procedure
1.

Culture cells in flat bottomed 96-well plates in a final volume of 100 uL/well
culture medium in a humidified atmosphere (e.g. 37°C, 5% C02). Reserve one
well as a background control (culture medium without cells).
Note: The incubation period and cell density of the culture depend on the
particular experimental conditions and on the cell line used. For most
experimental setups, a cell density between 103 and 5 x 104 cells/well and an
incubation time of 24 to 96 hr is appropriate.

2.

Add 10 uL of Premixed WST-1 Cell Proliferation Reagent to each well (1:10 final
dilution).
Note: Premixed WST-1 Cell Proliferation Reagent should be used at a final
dilution of 1:10. If cells are cultured in 200 uL culture medium, add 20 uL
Premixed WST-1 Cell Proliferation Reagent per well.

3.

Incubate the plate for 0.5 to 4 hr at 37°C in a humidified atmosphere maintained
at 5% C02.

4.

Measure the absorbance at 420-480 nm (maximum absorption is at ~440 nm),
using a spectrophotomeric plate reader. The reference wavelength should be
greater than 600 nm. Shake thoroughly for 1 minute before measurement.
Note: The absorbance level of the background control well (containing culture
medium plus Premixed WST-1 Cell Proliferation Reagent, without cells) will
depend on the culture medium, incubation time, and exposure to light. Typical
background absorbance after 2 hr is between 0.1-0.2 absorbance units.

APPENDIX D
IMMUNOCYTOCHEMICAL LOCALIZATION
OF CELLULAR ANTIGENS
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Materials and Equipment Needed
•
•
•
•
•
•
•
•
•
•
•

•

Cell culture media
HBSS without phenol red
95% ethanol
Kim wipes
Primary and secondary antibodies
Petri dishes
Coverslips or glass slides
Transfer pipettes
PBS
PBS-Tween
BrdU powder (if detecting BrdU)
Incorporate BrdU into cells by making a solution BrdU powder in HBSS
without phenol red to make a concentration of 5 mg/mL
NOTE: If BrdU is to be detected, BrdU must be incorporated into the cells at
least one day before immunocytochemistry.
Additionally, nuclear
permeabilization step must be done using a 1 N HC1 solution.
For Enzyme Substrate Detection:
• Anti-mouse Kit (ABC detection)
• DAB, HistoMark Orange or other chromagen
• Hematoxylin or Contrast Green
• Plastic box
For Fluorescent Detection:
0.25-0.5% Triton X-100 in PBS

Procedure
1.

Trypsinize cells and seed onto glass slides at appropriate density. Place a few
drops of cell suspension in the center of the coverslip

2.

Incubate at 37 C for 10 minutes (cells have not yet attached, so carry them
carefully so you don't disturb the cells)

3.

Add complete media around the cell area. DO NOT ADD ON TOP OF CELL
SUSPENSION AS THIS WILL DISTURB CELLS. You may then add enough
media to cover bottom of dish and glass slides so that cells do not become
dehydrated.

4.

Incubate overnight so that cells are allowed to attach.

5.

Verify attachment, if attachment has not occurred, add a few drops of media only
to the area in which the cells were placed. Do not remove any media. Check
back periodically.
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After cells have attached, remove excess mediafromPetri dishes and slides using
a non-sterile transfer pipette.
Fix cells with 95% ethanol, for 3-5 minutes (you should see a white residue)
Use KimWipes to gently remove moisture from around the cells. Then draw a
ring around the cells with a hydrophobic Pap Pen (this holds the subsequent
reactions within this area). Do not let ink from pen touch the cells. Label the
coverslips "Experiment" and "Control".
Rinse 5 times for 2 min in PBS-T to permeabilize the cell membrane.
If a peroxidase marker is used, block endogenous peroxidase by incubating in 3%
H2O2 in PBS of 10-30 minutes. If other marker is used, such as avidin-biotin, or
fluorescence, omit this step
Rinse 3 times for 5 min in PBS.
Block with 2-5% normal serum in PBS for 20 minutes (Normal serum should be
the same species as the secondary antibody is raised). Place open Petri dish into
plastic container with cover and incubate at room temperature.
Note: If using avidin-biotin detection system, avidin/biotin block may be needed
based on cell type. If you do, the avidin/biotin block should be done after normal
serum block
If antibody is to be complexed to a fluorescent marker, this should be done a few
minutes before this step and should be kept away from light.
Incubate experimental slides with primary antibody for 1 hour. Add same amount
of PBS to control slides.
Decant the primary antibody solution, and immediately wash the dish 3x5 min
with PBS. Do not let the cells dry at any step. Especially during washing, handle
each dish individually since leaving a washed dish without medium for even a
few seconds can allow drying in the center of the dish.
Add the secondary antibody and incubate for 30-60 minutes at room temperature.
Decant the secondary antibody and wash the cells 3x5 min in PBS.
If using the avidin/biotin detection method, apply one drop of ABC reagent
and incubate at room temperature for 30 minutes
NOTE: If using DAB as a chromagen, follow steps 18-27

18.

Make up DAB (unstable at room temp and light sensitive.. .must be made not
more than lhr before it is used):
•
•
•

Use tweezers to place one tablet into mixing bottle
Add 10 ml type I water and dissolve by shaking for 2-3 minutes
Add one drop of peroxide solution to mixing bottle and invert gently for
about 30 seconds.

19.

Wash cells immediately with PBS and then again for 5 minutes. Remove excess
moisture with KimWipe

20.

Apply DAB and incubate for 7-10 minutes in dark (place covered Petri dish in a
box or cut off light in hood.

21.

Terminate the reaction by washing with tap water (add and remove water a few
times). If a reaction has occurred the experimental cells should appear brown in
color.

22.

Add 3-4 drops of hematoxylin to cells and incubate for 5 minutes.

23.

Rinse in tap water by adding and removing until rinse water is colorless.

24.

Rinse in acid rinse by adding a small amount every 2-3 seconds about 10 times,
then pour back into glass container.

25.

Immediately rinse in tap water by adding and removing about 10 times.

26.

Add bluing solution to cells and incubate for 1 minute at room temperature.

27.

Rinse in tap water about 10 times.

28..

Remove from Petri dishes. Allow slips to air dry for approximately 5 minutes on
KimWipes.

29.

Fix the cells again using 3.7% formaldehyde freshly made as performed in the
initial fixation. The purpose of the second fixation is to crosslink the antibodies in
place and to prevent subsequent diffusion of label. If not post-fixed in this way,
localization may not be stable for more than a few hours.

the
30.

Mount the cells with mounting medium and coverslip. Anti-fading mounting
medium is needed for fluorescent applications.

APPENDIX E
MTT ASSAY
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Procedure
A

stock

solution

of

(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide (MTT) was prepared at 5 mg/mL in PBS. The stock solution was further diluted
in completed DMEM in a 1:10 ratio. The 10% working solution was freshly prepared
before each use. For each sampling point (4, 7, 14, 21 days) cell culture media was
decanted and the glass substrates for each treatment were rinsed thrice in HBSS without
phenol red. A volume of 100 uL of MTT working solution was added to the samples and
the cells were incubated for a period of 24 hours at 37C. Subsequent to the incubation
time, the purple formazan precipitate was dissolved with 100 uL of 70% isopropyl
alcohol. The solutions were then transferred to 96-well plates and absorbance was
immediately measured at 570 nm using a reference wavelength of 690 nm (Tecan
spectrophotometer).

APPENDIX F
CELL LYSIS PROTOCOL
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Procedure
Briefly, cells were lifted from substrates through trypsinization, transferred to 15
mL conical tubes, and collected by centrifugation at 1200 rpm for 5 minutes. Each pellet
was resuspended in 1.5 mL of cold PBS and centrifuged at 1200 rpm for 5 minutes at
4°C. Cells were resuspended in 150 uL cell lysis solution (Sigma) and kept on ice for 15
minutes. Finally, the preparation was centrifuged at 3200 rpm for 20 minutes at 4°C.
The supernatant was recovered and stored at -20°C until needed for further use.
Quant-iT™ PicoGreen® dsDNA reagent (Invitrogen) was used to quantify the
amount of DNA present in the samples' cell lysate. The PicoGreen reagent was diluted
1:200 in IX TE buffer and protected from light. In a black 96-well plate, 10 uL of cell
lysate was diluted in 90 uL TE buffer. The PicoGreen working solution was then added
to each sample in a volume of 100 uL. The plates were incubated for 5 minutes in the
dark. An excitation wavelength of 485 nm was used, and fluorescence intensity was read
at an emission wavelength of 538 nm (Tecan Genios Platereader).
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